

B/O Form PTO-4390		Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing Under 35 USC 371	Attorney's Docket Number HESS3006/REF
			U.S. Application Number of Known 09/926491
International Application Number PCT/GB00/01813	International Filing Date 11 May 2000	Priority Date Claimed 11 May 1999	
Title of Invention STEROID COMPOUNDS WITH A C17-ALKYL SIDE CHAIN AND AN AROMATIC A-RING FOR USE IN THERAPY			
Applicant(s) for DO/EO/US HESSE et al.			

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items under 35 USC 371:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 USC 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 USC 371.
3. ☒ This express request to begin national examination procedures (35 USC 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 USC 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed 35 USC 371(c)(2).
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☐ A translation of the International Application into English (35 USC 371(c)(2)).
- ☒ Amendments to the claims of the International Application under PCT Article 19 (35 USC 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
- ☐ A translation of the amendments to the claims under PCT Article 19 (35 USC 371(c)(3)).
- ☐ An oath or declaration of the inventor(s) (35 USC 371(c)(4)). (☐ Executed ☐ Unexecuted)
- ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 USC 371(c)(5)).

Items 11 to 16 below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: Applicants assert entitlement to small entity status

Application Number (if Known) 09/926491		International Application Number PCT/GB00/01813		Attorney's Docket Number HESS3006/REF	
				Calculations	PTO USE ONLY
17. The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): <input checked="" type="checkbox"/> Search report has been prepared by the EPO or JPO \$890.00 <input type="checkbox"/> International Preliminary Examination Fee paid to USPTO (37 CFR 1.482) \$710.00 <input type="checkbox"/> No International Preliminary Examination Fee paid to USPTO (37 CFR 1.482) but International Search Fee paid to USPTO (37 CFR 1.445(a)(2)) \$740.00 <input type="checkbox"/> Neither International Preliminary Examination Fee (37 CFR 1.482) nor International Search Fee (37 CFR 1.445(a)(2)) paid to USPTO \$1040.00 <input type="checkbox"/> International Preliminary Examination Fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT				\$	890.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).					
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	20 -20 =	0	× \$18.00	\$	0.00
Independent Claims	2 -3 =	0	× \$84.00	\$	0.00
Multiple Dependent Claims (if applicable)			+ \$280.00		
TOTAL OF ABOVE CALCULATIONS				\$	890.00
Reduction by ½ for filing by small entity, if applicable. Small Entity Status is asserted pursuant to 37 CFR 1.27 for this application.					
SUBTOTAL				\$	445.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					
TOTAL NATIONAL FEE					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.					
TOTAL FEES ENCLOSED				\$	445.00
				Amount to be:	
				Refunded:	
				Charged:	

- a. ☒ A check in the amount of **\$445.00** to cover the fees is enclosed.
- b. ☐ Please charge my Deposit Account Number 02-0200 in the amount of \$_____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account Number 02-0200. A duplicate copy of this sheet is enclosed.

Note: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

BACON & THOMAS, PLLC
 625 SLATERS LANE - FOURTH FLOOR
 ALEXANDRIA, VIRGINIA 223124-1176
 Phone: (703) 683-0500



23364
 PATENT TRADEMARK OFFICE

Respectfully submitted,

Richard E. Fichter

Richard E. Fichter
 Attorney for Applicant
 Registration Number: 26,382

DATE: November 13, 2001

09/926491

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HESSE et al.

U.S. National Phase of PCT/GB00/01813

Entry papers filed herewith November 13, 2001:

For: STEROID COMPOUNDS WITH A C17-ALKYL SIDE CHAIN
AND AN AROMATIC A-RING FOR USE IN THERAPY

Attention: PCT OFFICE

**PRELIMINARY AMENDMENT
AND INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The present application is the U.S. national phase of international application number PCT/GB00/01813.

Please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please add the attached ABSTRACT OF THE DISCLOSURE to the application.

IN THE CLAIMS:

Please replace claims 5, 8-9, 11, 13, 17 and 19-20 with the following amended claims.

5(Amended). Compounds of formula (I) as claimed in claim 1 wherein R⁴ a hydrogen atom, a silyl group, a C₁₋₆ alkyl group optionally interrupted by one or more oxygen atoms or substituted by a lower cycloalkyl group, a cyclic ether group, a C₁₋₆

C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkanoyl, C₁₋₄ alkylamino, di(C₁₋₄ alkyl)amino, nitro, carbamoyl or C₁₋₄ alkanoylamino substituents; and

R⁷ is a hydrogen atom or a C₁₋₆ alkyl group.

5

10. Compounds of formula (I) as claimed in claim 9 wherein X represents a hydroxyl, amino, methylamino, ethylamino, N-ethyl-N-methylamino, acetylamino, benzamido or phenylacetylamino group.

10

11. Compounds of formula (I) as claimed in any of the preceding claims wherein Y contains up to 7 carbon atoms and up to 3 multiple bonds.

15

12. Compounds of formula (I) as claimed in claim 11 wherein Y is a straight chain C₂₋₆ group.

20

13. Compounds of formula (I) as claimed in any of the preceding claims wherein Y is substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group positioned α -, β - or γ - to the group -C(R¹)(R²).X or α - to any triple bond present in the group Y.

25

14. Compounds as claimed in claim 11 wherein Y is selected from ethylene, trimethylene, tetramethylene, vinylene, buta-1,3-dienylene, prop-2-ynylene and 1-hydroxyprop-2-ynylene.

30

15. Compounds of formula (I) as claimed in claim 1 wherein:

R¹ and R², which may be the same or different, each represents a lower alkyl group;

R⁵ represents a hydrogen atom; and

X represents a group NR⁶R⁷ wherein R⁷ is hydrogen.

35

alkanoyl group, an aroyl group, a C₁₋₆ alkane sulphonyl or halogenated methane sulphonyl group, or an arene sulphonyl group.

8(Amended). Compounds of formula (I) as claimed in claim 1 wherein R⁵ represents a hydrogen atom or a methoxy group.

9(Amended). Compounds of formula (I) as claimed in claim 1 wherein X represents a hydroxyl group or a group of formula NR⁶R⁷ wherein:

R⁶ is a C₁₋₆ alkyl group, C₆₋₁₂ carbocyclic aryl C₁₋₄ alkyl group, C₁₋₆ alkanoyl group, C₆₋₁₂ carbocyclic aryl C₂₋₅ alkanoyl group, C₇₋₁₃ carbocyclic aroyl group or any of the preceding groups substituted by one or more halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkanoyl, C₁₋₄ alkylamino, di (C₁₋₄ alkyl) amino, nitro, carbamoyl or C₁₋₄ alkanoylamino substituents; and

R⁷ is a hydrogen atom or a C1-6 alkyl group.

11(Amended). Compounds of formula (I) as claimed in claim 1 wherein Y contains up to 7 carbon atoms and up to 3 multiple bonds.

13(Amended). Compounds of formula (I) as claimed in claim 1 wherein Y is substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group positioned α-, β- or γ- to the group -C(R¹) (R²), X or α- to any triple bond present in the group Y.

17(Amended). Active compound of formula (I) as claimed in claim 1 for use in management of neoplastic disease; as agents to promote wound healing; in burn management; in treatment of bone diseases, autoimmune disease, host-graft reaction, transplant rejection, inflammatory diseases, neoplasias or hyperplasias, myopathy, enteropathy or spondylitic heart disease; in suppression of parathyroid hormone; in treatment of dermatological diseases, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism, asthma, cognitive impairment or senile

dementia; in fertility control in either human or animal subjects; in management of disorders involving blood clotting; or in reduction of serum cholesterol.

19(Amended). Pharmaceutical compositions comprising an active compound of formula (I) as claimed in claim 1 in admixture with one or more physiologically acceptable carriers or excipients.

20(Amended). A method of treatment of a human or animal subject in the management of neoplastic disease; to promote wound healing; in burn management; in treatment of bone diseases, autoimmune disease, host-graft reaction, transplant rejection, inflammatory diseases, neoplasias or hyperplasias, myopathy, enteropathy or spondylitic heart disease; in suppression of parathyroid hormone; in treatment of dermatological diseases, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism, asthma, cognitive impairment or senile dementia; in fertility control; in management of disorders involving blood clotting; or in reduction of serum cholesterol, which method comprises administering to said subject a therapeutically effective amount of an active compound of formula (I) as claimed in claim 1.

Please cancel claim 18 without prejudice or disclaimer.

REMARKS

Applicants have amended the claims in order to reduce the initial filing fee by deleting the improper use claim 18 and by deleting the multiple dependent claims from the application. Applicants retain the right to reintroduce any subject matter canceled by the present Amendment at any time during the prosecution of this application or any further application claiming benefit of this application. Also, an Abstract of the Disclosure has been added to the application.


Applicants are submitting herewith a copy of the Search Report which issued on International Application No. PCT/GB00/01813, of which the present application is the U.S. national phase. All of the publications cited in the International Search Report are listed on the attached Form PTO-1449. It is Applicants' understanding that, under the procedures of the PCT, copies of the cited publications will have been supplied to the U.S. Patent Office by the International Bureau. However, the Examiner is invited to contact the undersigned attorney if additional copies are necessary or would facilitate examination of the present application.

Otherwise, the Examiner is respectfully requested to return an initialed and dated copy of the attached Form PTO-1449 to confirm that all publications listed thereon have been considered and made officially of record in the file of this application.

Applicants understand that, under the procedures of the PCT, a copy of the priority document (9910934.0, filed 11 May 1999) will have been supplied to the U.S. Patent Office pursuant to Rule 17 of the PCT Regulations. It is therefore respectfully requested that the first Official Action in the present application contain an indication that the appropriate priority document is in the file of this application.

In view of the above amendments, an early action on the application is now in order and is most respectfully requested.

Respectfully submitted,
BACON & THOMAS, PLLC

By: 
RICHARD E. FICHTER
Registration No. 26,382

625 Slaters Lane - 4th Floor
Alexandria, Virginia 22314
Phone: (703) 683-0500
Facsimile: (703) 683-1080

REF:kdd
PA01.wpd

DATE: November 13, 2001

Marked-Up Version Showing Changes Made

IN THE CLAIMS:

Please replace claims 5, 8-9, 11, 13, 17 and 19-20 with the following amended claims.

5(Amended). Compounds of formula (I) as claimed in [any of the preceding claims] claim 1 wherein R⁴ a hydrogen atom, a silyl group, a C₁₋₆ alkyl group optionally interrupted by one or more oxygen atoms or substituted by a lower cycloalkyl group, a cyclic ether group, a C₁₋₆ alkanoyl group, an aroyl group, a C₁₋₆ alkane sulphonyl or halogenated methane sulphonyl group, or an arene sulphonyl group.

8(Amended). Compounds of formula (I) as claimed in [any of the preceding claims] claim 1 wherein R⁵ represents a hydrogen atom or a methoxy group.

9(Amended). Compounds of formula (I) as claimed in [any of the preceding claims] claim 1 wherein X represents a hydroxyl group or a group of formula NR⁶R⁷ wherein:

R⁶ is a C₁₋₆ alkyl group, C₆₋₁₂ carbocyclic aryl C₁₋₄ alkyl group, C₁₋₆ alkanoyl group, C₆₋₁₂ carbocyclic aryl C₂₋₅ alkanoyl group, C₇₋₁₃ carbocyclic aroyl group or any of the preceding groups substituted by one or more halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkanoyl, C₁₋₄ alkylamino, di (C₁₋₄ alkyl) amino, nitro, carbamoyl or C₁₋₄ alkanoylamino substituents; and

R⁷ is a hydrogen atom or a C1-6 alkyl group.

11(Amended). Compounds of formula (I) as claimed in [any of the preceding claims] claim 1 wherein Y contains up to 7 carbon atoms and up to 3 multiple bonds.

13(Amended). Compounds of formula (I) as claimed in [any of the preceding claims] claim 1 wherein Y is substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group positioned α -, β - or γ - to the group $-C(R^1)(R^2)$, X or α - to any triple bond present in the group Y.

17(Amended). Active compound of formula (I) as claimed in [any preceding claim] claim 1 for use in management of neoplastic disease; as agents to promote wound healing; in burn management; in treatment of bone diseases, autoimmune disease, host-graft reaction, transplant rejection, inflammatory diseases, neoplasias or hyperplasias, myopathy, enteropathy or spondylitic heart disease; in suppression of parathyroid hormone; in treatment of dermatological diseases, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism, asthma, cognitive impairment or senile dementia; in fertility control in either human or animal subjects; in management of disorders involving blood clotting; or in reduction of serum cholesterol.

19(Amended). Pharmaceutical compositions comprising an active compound of formula (I) as claimed in [any one of claims 1 to 16] claim 1 in admixture with one or more physiologically acceptable carriers or excipients.

20(Amended). A method of treatment of a human or animal subject in the management of neoplastic disease; to promote wound healing; in burn management; in treatment of bone diseases, autoimmune disease, host-graft reaction, transplant rejection, inflammatory diseases, neoplasias or hyperplasias, myopathy, enteropathy or spondylitic heart disease; in suppression of parathyroid hormone; in treatment of dermatological diseases, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism, asthma, cognitive impairment or senile dementia; in fertility control; in management of disorders involving blood clotting; or in reduction of serum cholesterol, which method comprises administering to said subject a

therapeutically effective amount of an active compound of formula (I) as claimed in [any of claim s 1 to 16] claim 1.

ABSTRACT OF THE DISCLOSURE

Compounds of Formula (I) in which: R^1 and R^2 , which may be the same or different, each represents a lower alkyl, alkenyl or alkynyl group; R^3 represents a methyl group having α - or β -configuration; R^4 represents a hydrogen atom or an etherifying or esterifying group; R^5 represents a hydrogen atom, a hydroxyl group or a lower alkoxy group; X represents a group OR^4 , wherein R^4 is as defined above, or a group NR^6R^7 wherein R^6 represents a hydrogen atom, an aliphatic or araliphatic organic group, or an acyl group comprising an aliphatic, araliphatic or aryl organic group linked to the nitrogen atom by way of a carbonyl group; and R^7 is a hydrogen atom or a lower alkyl group; Y represents a lower alkylene, alkenylene or alkynylene group optionally substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group; and the dotted lines signify that double bonds may be present at the 16(17)-position and/or either at the 6(7)- and 8(9)-positions or at the 7(8)-position exhibit potent effects on modulation of cell growth and differentiation, while having low calcaemic activity.

205220 "T 6492550

- 1 -

STEROID COMPOUNDS WITH A C17-ALKYL SIDE CHAIN AND AN AROMATIC A-RING
FOR USE IN THERAPY

5 This invention relates to novel sterol derivatives,
more particularly to ring A aromatic sterol derivatives
in which the 17-position side chain terminates in an
amino, amido or hydroxyl group and which exhibit cell
modulating activity.

10 It is well known that 9,10-seco sterol derivatives
such as vitamin D₃ play a vital role in the metabolism of
calcium by promoting intestinal absorption of calcium
and phosphorus, maintaining adequate serum levels of
calcium and phosphorus, and stimulating mobilisation of
15 calcium from the bone fluid compartment in the presence
of parathyroid hormone. Following the discovery that D
vitamins are hydroxylated *in vivo*, at the 25-position in
the liver and at the 1 α -position in the kidneys, and
that the resulting 1 α ,25-dihydroxy metabolite is the
biologically active material, extensive studies have
20 been carried out on vitamin D analogues hydroxylated at,
for example, the 1 α - and 24R- or 25-positions.

25 The natural metabolite 1 α ,25-dihydroxy vitamin D₃
has additionally been found to have effects on cellular
metabolism, these cell modulating effects including
stimulation of cell maturation and differentiation,
immunosuppressive effects and immunopotentiating effects
(e.g. by stimulating the production of bactericidal
oxygen metabolites and the chemotactic response of
leukocytes). However, the potent effects of compounds
30 such as 1 α ,25-dihydroxy vitamin D₃ on calcium metabolism
will normally preclude their use in this area, since
doses sufficient to elicit a desired cell modulating
effect will tend to lead to unacceptable hypercalcaemia.

35 This has led to attempts to synthesize new vitamin
D analogues which have reduced effects on calcium
metabolism but which still exhibit the desired effects
on cellular metabolism. Representative examples of such

analogues, together with summaries of earlier attempts to solve this problem, are given in WO-A-9309093, WO-A-9426707, WO-A-9525718 and WO-A-9516672, the contents of which are incorporated herein by reference.

5 It is currently believed that such vitamin D analogues act as general regulators of cell growth and differentiation through receptor-mediated (especially nuclear receptor-mediated) processes involving modulation of vitamin D responsive genes (M.R. Waters,
10 Endoc. Rev. 13, pp. 719-764 [1992]). It has also hitherto been assumed that the seco steroid 5,7,10(19)-triene system or a similar 19-nor seco steroid 5,7-diene system is a prerequisite for any form of cell modulating activity. Thus, whilst workers investigating vitamin D
15 analogues have modified the A-ring and 17-position side chain and in certain cases have made more drastic modifications to the overall molecular skeleton such as modification or even elimination of the C- and/or D-rings, they have attempted to retain the triene or
20 conjugated diene system (Gui-Dong Zhu et al., Bioorganic & Med. Chem. Lett. 6, pp. 1703-1708 [1996]; K. Sabbe et al., Bioorganic & Med. Chem. Lett. 6, pp. 1697-1702 [1996]).


Workers have recently reported the observation of
25 non-genomic rapid responses to vitamin D analogues which they attribute to interaction with a putative cell membrane-located vitamin D receptor (A.W. Norman et al., J. Steroid Biochem. and Mol. Biol. 56, pp. 13-22 [1996]). It has also been reported that such non-
30 genomic rapid effects may be elicited by $1\alpha,3\beta,25$ -trihydroxycholesta-5,7-diene, i.e. the pro-vitamin form of $1\alpha,25$ -dihydroxy vitamin D₃, which is not a seco steroid; this has been attributed to the ability of the pro-vitamin to mimic the 6,7-s-cis conformation of the
35 normal vitamin D triene (Norman, *op. cit.*). However, the pro-vitamin has been reported to have little ability to elicit the genomic effect believed to underlie

modulation of cell growth and differentiation (Norman, *op. cit.*) and has also been reported not to exhibit the typical effects of vitamin D on skin (R. Gniadecki et al., *British J. Dermatol.* **132**, pp. 841-852 [1995]).

5 The present invention is based on the surprising finding that a range of simple sterol derivatives which have an intact tetracyclic nucleus and lack both the seco steroid triene system of vitamin D analogues and the ability to mimic a conjugated conformational isomer thereof, exhibit potent effects on the modulation of
10 cell growth and differentiation, for example as demonstrated by their ability to inhibit growth of cancer cells *in vitro* and *in vivo*, and their ability to promote the healing of ear punches *in vivo*. The compounds possess an advantageous therapeutic ratio by
15 virtue of their low levels of calcaemic activity, for example as determined by their effects on serum calcium and phosphorus levels in rats.

The compounds of the invention comprise 3-sterols
20 (and O-protected derivatives thereof) having an aromatic A ring and an amine-, amide- or hydroxyl-terminated 17-position side chain. The compounds may also contain an aromatic B-ring or a double bond at the 7(8)-position and/or a double bond at the 16(17)-position.

25 Thus according to one embodiment of the invention there are provided compounds of formula (I)



in which:

R^1 and R^2 , which may be the same or different, each represents a lower alkyl, alkenyl or alkynyl group;

R^3 represents a methyl group having α - or β -
5 configuration;

R^4 represents a hydrogen atom or an etherifying or esterifying group;

R^5 represents a hydrogen atom, a hydroxyl group or a lower alkoxy group;

10 X represents a group OR^4 , wherein R^4 is as defined above, or a group NR^6R^7 wherein R^6 represents a hydrogen atom, an aliphatic or araliphatic organic group, or an acyl group comprising an aliphatic, araliphatic or aryl organic group linked to the nitrogen atom by way of a
15 carbonyl group; and R^7 is a hydrogen atom or a lower alkyl group;

Y represents a lower alkylene, alkenylene or alkynylene group optionally substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group; and

20 the dotted lines signify that double bonds may be present at the 16(17)-position and/or either at the 6(7)- and 8(9)-positions or at the 7(8)-position.

R^1 and R^2 may, for example, be selected from lower (e.g. C_{1-6}) alkyl groups such as methyl, ethyl, propyl
25 and butyl groups, lower (e.g. C_{2-7}) alkenyl groups such as allyl, and lower (e.g. C_{2-7}) alkynyl groups such as propargyl. Where appropriate the groups may be straight chain or branched; straight chain groups may be preferred.

30 Where R^3 in formula (I) is a methyl group in the α -configuration, the compounds have the 20R configuration characteristic of natural sterols such as cholesterol; where R^3 is in the β -configuration the compounds have the 20S configuration of the corresponding epi-derivatives.
35 It will be appreciated that the invention also embraces mixtures of the two isomers.

Where R^4 represents an etherifying or an esterifying

group this may, for example, comprise any suitable cleavable O-protecting group such as is commonly known in the art. Such O-protected derivatives of compounds of formula (I) are useful in the preparation of active compounds (I) in which R^4 represents a hydroxy group and may also, where the O-protecting group is either metabolically labile *in vivo* or is a lower alkyl etherifying group such as methyl, ethyl or isobutyl, be useful directly in therapy. Representative O-protecting groups include (i) etherifying groups such as silyl groups (e.g. tri(lower alkyl)silyl groups such as trimethylsilyl, triethylsilyl, triisopropylsilyl or t-butyl dimethylsilyl; tri(aryl)silyl groups such as triphenylsilyl; and mixed alkyl-arylsilyl groups), lower (e.g. C_{1-6}) alkyl groups optionally interrupted by one or more oxygen atoms (e.g. such as methyl, ethyl methoxymethyl or methoxyethoxymethyl) or substituted by a lower (e.g. C_{2-8}) cycloalkyl group (e.g. as in cyclopentylmethyl), and cyclic ether groups (e.g. such as tetrahydropyranyl), and (ii) esterifying groups such as lower (e.g. C_{1-6}) alkanoyl (e.g. such as acetyl, propionyl, isobutyryl or pivaloyl), aroyl (e.g. containing 7-15 carbon atoms, such as benzoyl or 4-phenylazobenzoyl), lower (e.g. C_{1-6}) alkane sulphonyl (e.g. such as methane sulphonyl or halogenated methane sulphonyl) and arene sulphonyl (e.g. such as p-toluene sulphonyl). Where appropriate the groups may be straight chain or branched.

Where R^5 represents a lower alkoxy group, this may for example be a straight chain or branched C_{1-6} alkoxy group such as a methoxy, ethoxy or propoxy group.

Where R^6 represents an aliphatic group this may, for example, be a lower alkyl group, for example a straight chain C_{1-6} alkyl group such as a methyl, ethyl, propyl or butyl group. Aliphatic groups R^6 may, for example, include C_{6-12} carbocyclic aryl C_{1-4} alkyl groups such as benzyl or phenethyl. Where R^6 represents an acyl group

206220 "T 6492660

this may, for example, be a lower (e.g. C₁₋₆) alkanoyl group such as formyl, acetyl or propionyl; a C₆₋₁₂ carbocyclic aryl C₂₋₅ alkanoyl group such as phenylacetyl; or a C₇₋₁₃ carbocyclic aroyl group such as benzoyl. The group R⁶ may optionally carry one or more substituents, for example selected from halo (e.g. chloro or bromo), lower (e.g. C₁₋₄) alkyl such as methyl, lower alkoxy (e.g. methoxy), lower alkanoyl (e.g. acetyl), lower alkylamino (e.g. methylamino), di(lower alkyl)amino (e.g. dimethylamino), nitro, carbamoyl and lower alkanoylamino (e.g. acetamido).

When R⁷ represents a lower alkyl group, this may, for example, be a straight chain or branched C₁₋₆ alkyl group such as a methyl, ethyl, propyl or butyl group.

Lower alkylene, alkenylene or alkynylene groups represented by Y may, for example, contain up to 7 carbon atoms and up to 3 multiple bonds. Y may advantageously be a straight chain group, e.g. containing 2-6 carbon atoms, for example as in ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, vinylene, buta-1,3-dienylene, propynylene (e.g. prop-2-ynylene), but-1-ynylene or but-2-ynylene.

Where Y is substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group, this substituent may advantageously be positioned α -, β - or γ - to the group -C(R¹)(R²).X or α - to any triple bond present in the group Y, e.g. as in 1-hydroxyprop-2-ynylene. Etherifying groups which may be present include lower (e.g. C₁₋₆) alkyl groups optionally interrupted by one or more oxygen atoms (e.g. methyl, methoxymethyl or methoxyethoxymethyl), and cyclic groups such as tetrahydropyranyl. Esterifying groups which may be present include lower (e.g. C₁₋₆) alkanoyl such as acetyl, propionyl, isobutyryl or pivaloyl; lower alkenoyl (e.g. allylcarbonyl); aroyl (e.g. p-nitrobenzoyl); lower alkoxycarbonyl (e.g. t-butoxycarbonyl); lower haloalkoxycarbonyl (e.g. 2,2,2-

trichloroethoxycarbonyl or 1,1,1-trichloro-2-methyl-2-propoxycarbonyl); aralkyloxycarbonyl (e.g. benzyloxycarbonyl or p-nitrobenzyloxycarbonyl); and lower alkenyloxycarbonyl (e.g. allyloxycarbonyl). It will be appreciated that it may be advantageous to select etherifying or esterifying groups which are metabolically labile *in vivo*.

The cell modulating activity of compounds according to the invention, including O-protected derivatives in which the O-protecting group is metabolically labile, combined with their substantial lack of calcaemic effect, render them of interest both alone and as adjuncts in the management of diseases associated with abnormal cell proliferation, such as neoplastic disease, particularly myelogenous leukemias as well as neoplastic disease of the brain, breast, stomach, gastrointestinal tract, prostate, pancreas, uro-genital tract (male and female) and pulmonary neoplasia. Their ability to promote closure of mouse ear punches suggests their use, either alone or as adjuncts, as agents to promote wound healing. Compounds of the invention also appear to promote healing of experimental burns, suggesting a utility in burn management. The cell modulating activity of compounds of the invention suggests that they may, like vitamin D analogues, have additional utilities either alone or as adjuncts in the chemotherapy of infection and in other therapeutic modalities in which mononuclear phagocytes are involved, for example in treatment of bone disease (e.g. osteoporosis, osteopenia and osteodystrophy as in rickets or renal osteodystrophy), autoimmune disease, host-graft reaction, transplant rejection, inflammatory diseases (including modulation of immunoinflammatory reactions), neoplasias and hyperplasias, myopathy, enteropathy and spondylitic heart disease, their potential utility in treatment of neoplasias and hyperplasias being evidenced by their ability to inhibit

human cancer xenografts in severe combined immunodeficiency mice. Additionally, they may be useful in suppression of parathyroid hormone (e.g. as in serum calcium homeostasis), in treatment of dermatological diseases (for example including acne, alopecia, eczema, pruritus, psoriasis and skin aging, including photoaging), hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism, asthma, cognitive impairment and senile dementia (including Alzheimer's disease), in fertility control in both human and animal subjects, and in management of disorders involving blood clotting (e.g. by dissolution of existing clots and/or by prevention of clotting). The invention embraces use of these compounds in the therapy or prophylaxis of such conditions and in the manufacture of medicaments for use in such treatment or prophylaxis.

Compounds of the invention have also been found to bind to oestrogen receptors, whilst being free from and even inhibiting uterotrophic effects such as are associated with conventional oestrogens. This binding effect, in combination with their anabolic wound healing effects, suggests that such compounds may additionally be useful in prevention or treatment of osteoporosis and in reduction of serum cholesterol.

Active compounds according to the invention may be formulated for administration by any convenient route, e.g. orally (including sublingually), parenterally, rectally or by inhalation; pharmaceutical compositions so formulated comprise a feature of the invention.

Orally administrable compositions may, if desired, contain one or more physiologically compatible carriers and/or excipients and may be solid or liquid. The compositions may take any convenient form including, for example, tablets, coated tablets, capsules, lozenges, aqueous or oily suspensions, solutions, emulsions, syrups, elixirs and dry products suitable for

reconstitution with water or another suitable liquid vehicle before use. The compositions may advantageously be prepared in dosage unit form. Tablets and capsules according to the invention may, if desired, contain
5 conventional ingredients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth or polyvinyl-pyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; lubricants, for example magnesium stearate,
10 talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate. Tablets may be coated according to methods well known in the art.

Liquid compositions may contain conventional
15 additives such as suspending agents, for example sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxymethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan
20 monooleate or acacia; non-aqueous vehicles, which may include edible oils, for example vegetable oils such as arachis oil, almond oil, fractionated coconut oil, fish-liver oils, oily esters such as polysorbate 80, propylene glycol, or ethyl alcohol; and preservatives,
25 for example methyl or propyl p-hydroxybenzoates or sorbic acid. Liquid compositions may conveniently be encapsulated in, for example, gelatin to give a product in dosage unit form.

Compositions for parenteral administration may be
30 formulated using an injectable liquid carrier such as sterile pyrogen-free water, sterile peroxide-free ethyl oleate, dehydrated alcohol or propylene glycol or a dehydrated alcohol/propylene glycol mixture, and may be injected intravenously, intraperitoneally or
35 intramuscularly.

Compositions for rectal administration may be formulated using a conventional suppository base such as

- 10 -

cocoa butter or another glyceride.

Compositions for administration by inhalation are conveniently formulated for self-propelled delivery, e.g. in metered dose form, for example as a suspension in a propellant such as a halogenated hydrocarbon filled into an aerosol container provided with a metering dispense valve.

It may be advantageous to incorporate an antioxidant, for example ascorbic acid, butylated hydroxyanisole or hydroquinone in the compositions of the invention to enhance their storage life.


Where any of the above compositions are prepared in dosage unit form these may for example contain 10 μ g - 100 mg, preferably 100 μ g - 100 mg of active compound according to the invention per unit dosage form; such dosage units may for example be administered 1-4 times per day. The compositions may if desired incorporate one or more further active ingredients.

A suitable daily dose of an active compound according to the invention may for example be in the range 100 μ g - 400 mg, per day, depending on factors such as the severity of the condition being treated and the age, weight and condition of the subject.

Compounds according to the invention may be prepared by any convenient method, for example by reaction of a compound containing a precursor for the desired 17-position side chain in one or more stages and with one or more reactants serving to form the said desired 17-position side chain, followed if necessary and/or desired by removal of any O-protecting group.


Appropriate techniques for formation of a desired side chain include those described in the aforementioned WO-A-9516672.

Thus, for example, in order to prepare a compound (I) in which R^1 and R^2 are identical and X is the group NR^6R^7 in which R^6 and R^7 are hydrogen atoms, a compound of general formula (II)




(where R^3 , R^4 , R^5 and Y are as hereinbefore defined) may be reacted with an organo-cerium reagent, e.g. prepared in situ from cerous chloride and an appropriate organometallic compound, e.g. an alkyl/cycloalkyl lithium compound of formula R^1Li (where R^1 is as hereinbefore defined), for example as described by Ciganek (J. Org. Chem. 57, pp. 4521-4527 [1992]).

Compounds of formula (I) in which R^1 and R^2 are different and X is the group NR^6R^7 in which R^6 and R^7 are hydrogen atoms may, for example, be prepared by reacting a thio-oxime of formula (III)



(where R^1 , R^3 , R^4 , R^5 and Y are as hereinbefore defined and R^8 is an aromatic group, e.g. a carbocyclic aryl group such as phenyl) with an appropriate organometallic compound, for example an alkyl/cycloalkyl lithium compound of formula R^2Li (where R^2 is as hereinbefore defined), and reducing the thus-obtained compound of formula (IV)



10 (where R^1 , R^2 , R^3 , R^4 , R^5 , R^8 and Y are as hereinbefore defined), e.g. using a metal hydride reducing agent such as sodium borohydride or an inorganic or organic sulphur compound such as hydrogen sulphide, sodium sulphide or a thiol (e.g. a lower alkyl mercaptan such as

15 methanethiol) to remove the $R^8.S$ group and yield a corresponding compound of formula (I) in which X is the group NR^6R^7 in which R^6 and R^7 represent hydrogen atoms (see J. Org. Chem. 42, pp. 398-399 [1977]).

20 Compounds of formula (I) where X is a group NR^6R^7 in which R^6 represents a lower alkanoyl, aralkanoyl or aroyl group and R^7 represents a hydrogen atom may be prepared by acylation of a corresponding compound (I) in which R^6 is hydrogen, for example by reaction with an appropriate acyl halide or acid anhydride, preferably in the

25 presence of water or a lower alcohol, as may typically be incorporated to suppress acylation of groups other than the amino group, or with an appropriate acid in the presence of a coupling agent such as N,N'-carbonyl-diimidazole or dicyclohexylcarbodiimide. It will be

30 appreciated that if the acylation is carried out in the absence of components such as water or lower alcohols which suppress the acylation of hydroxyl groups, then any hydroxyl groups present in the molecule, e.g. at the 2- or 3-position or as a substituent of the Y group,

35 should desirably be in O-protected form during such an acylation reaction.


Compounds of formula (I) where X is a group NR^6R^7 in

- 13 -

which R^6 represents an aliphatic or araliphatic group and R^7 represents a hydrogen atom may, for example, be prepared by reducing a corresponding compound (I) in which R^6 is an aliphatic or araliphatic acyl group, e.g. using a metal hydride reducing agent such as lithium aluminium hydride.

Compounds of formula (I) where X is a group NR^6R^7 in which at least one of R^6 and R^7 represents a hydrogen atom may be subjected to appropriate substitution reactions to introduce desired R^6 and/or R^7 groups, for example to direct alkylation, e.g. by reaction with an alkyl halide, or to reductive amination, e.g. by reaction with an appropriate aldehyde and a reducing agent such as sodium cyanoborohydride.


Compounds of formula (I) in which X is a hydroxyl group may, for example, be prepared by reaction of a compound of formula (V)



(where R^1 , R^3 , R^4 , R^5 and Y are as hereinbefore defined) with an appropriate organometallic compound, for example a compound of formula R^2Li (where R^2 is as hereinbefore defined).


Compounds of formula (I) in which X is a hydroxyl group and R^1 and R^2 are identical may similarly be prepared by reaction of a compound of formula (VI)

- 14 -




(where R^3 , R^4 , R^5 and Y are as hereinbefore defined and R^9 is a lower [e.g. C_{1-6}] alkyl group such as methyl, ethyl, isopropyl or isoamyl) with an excess of an appropriate organometallic compound, for example a compound of formula R^1Li (where R^1 is as hereinbefore defined and is identical to R^2).

Compounds of formula (I) in which Y is an alkynylene group may, for example, be prepared by reaction of a compound of formula (VII)




(where R^3 , R^4 and R^5 are as hereinbefore defined; Y^a is an alkylene group, e.g. containing 1-4 carbon atoms; and L represents a leaving group, for example a sulphonate ester group, e.g. lower alkyl sulphonyloxy such as mesyloxy, lower fluoroalkyl sulphonyloxy such as trifluoromethanesulphonyloxy or aryl sulphonyloxy such as tosyloxy, or a halogen atom such as chlorine, bromine or iodine), with a metallated derivative (e.g. the lithio derivative) of an alkyne of formula (VIII)



5 (where R^1 , R^2 and X are as hereinbefore defined and n is 0 or an integer, e.g. in the range 1-3).

The thus obtained compound (I) in which Y is the group




10

(wherein Y^a and n are as hereinbefore defined) may if desired be hydrogenated to convert the triple bond either to a double bond (e.g. using Lindlar catalyst) or to a single bond (e.g. using a noble metal catalyst such as platinum, palladium or homogeneous rhodium or ruthenium).

15

Compounds of formula (I) in which Y is an alkynylene group carrying a hydroxyl group α to the triple bond may, for example, be prepared by reaction of a compound of formula (IX)


20



25

30 (where R^3 , R^4 and R^5 are as hereinbefore defined and Y^b is a valence bond or an alkylene group, e.g. containing 1-4 carbon atoms) with a metallated derivative of an alkyne of formula (VIII), so as to form a compound (I) in which Y is a group


35



- 16 -

(wherein Y^b and n are as hereinbefore defined).

Compounds of formula (VIII) may be prepared by
subjecting a compound of formula (X)




(where n , R^1 and R^2 are as hereinbefore defined) to a
Ritter reaction with a compound of formula R^aCN (where R^a
represents a hydrogen atom or an appropriate organic
10 group) in the presence of a strong acid, e.g. a mineral
acid such as sulphuric acid, thereby leading to
formation of a compound (I) where X is the group NR^6R^7 in
which R^6 represents a group $\text{R}^a.\text{CO}-$ and R^7 is a hydrogen
atom. The R^6 group may be removed by hydrolysis to yield
15 a compound (I) in which R^6 represents a hydrogen atom or
may be reduced, e.g. as hereinbefore described, to yield
a compound (I) in which R^6 represents a group $\text{R}^a.\text{CH}_2-$.
Alternatively the hydroxyl group of the tertiary
carbinol may be displaced by an azido group, e.g. by
20 reaction with hydrazoic acid in the presence of a strong
acid, and the azido group reduced to yield a compound
(I) where X is the group NR^6R^7 in which R^6 and R^7
represent hydrogen atoms. The internal alkyne group may
then be isomerized to the terminal position by treatment
25 with the potassium salt of 1,3-propanediamine in 1,3-
propanediamine as solvent ("acetylene zipper").

Compounds of formula (II) may, for example,
themselves be prepared by reaction of a compound of
formula (VII) as defined above with, as appropriate, (i)
30 a source of cyanide ion (e.g. an alkali metal cyanide
such as sodium or potassium cyanide), (ii) a metallated
acetonitrile derivative (e.g. the lithio derivative), or
(iii) acrylonitrile, preferably where L is an iodine
atom (e.g. by ultrasound-induced chromium-mediated
35 conjugate addition as described by Mourino et al. in J.
Org. Chem. **58**, pp. 118-123 [1993]).

Compounds (II) in which the 17-position side chain

terminates in the group $-\text{CH}:\text{CH}.\text{CN}$ may, for example, be prepared from an aldehyde of formula (IX) as defined above by means of a Wittig reaction with an ylid of formula $(\text{R}^{10})_3\text{P}:\text{CH}.\text{CN}$ (where each R^{10} represents an organic group, e.g. a carbocyclic aryl group such as phenyl) or with a corresponding phosphonate or silyl equivalent.

Compounds of formula (III) may, for example, themselves be prepared by reacting a ketone of formula (V) with an S-substituted thiolamine of formula $\text{R}^8.\text{S}.\text{NH}$ (where R^8 is as hereinbefore defined). Such compounds of formula (V) may, for example, be prepared from an acid of formula (XI)



(XI)

(where R^3 , R^4 , R^5 and Y are as hereinbefore defined), e.g. by formation of a corresponding acid halide such as the chloride and reaction with an organometallic compound R^1MX (where R^1 is as hereinbefore defined; M represents a divalent metal such as copper, zinc or cadmium; and X represents e.g. a halogen atom). Alternatively one may prepare compounds (V) by reacting a compound of formula (VII) above with e.g. (i) an α -metallated derivative such as a lithio derivative of a ketone of formula $\text{CH}_3.\text{CO}.\text{R}^1$ (where R^1 is as hereinbefore defined) or with a corresponding enol, or (ii), preferably where L is an iodine atom, a vinyl ketone of formula $\text{CH}_2:\text{CH}.\text{CO}.\text{R}^1$ (where R^1 is as hereinbefore defined), e.g. by ultrasound-induced chromium-mediated conjugate addition as described by Mourino et al. (op.

cit.).

Compounds (XI) and esters thereof, e.g. compounds of formula (VI), may also be used to prepare compounds of formula (II) by reaction with ammonia or a metallated derivative thereof, e.g. an alkali metal amide such as lithium amide, to form a corresponding carboxamide which may be converted to a nitrile (II) by mild dehydration, e.g. using tosyl chloride, phosphorus oxychloride in the presence of a base such as pyridine, or trifluoroacetic anhydride in the presence of an excess of a base such as pyridine.

Compounds (II) in which Y is α -substituted by a hydroxyl group are conveniently obtained by cyanohydrin formation, for example by reaction of a compound (IX) with hydrogen cyanide. Compounds (II) in which Y is β -substituted by a hydroxyl group may be prepared directly by reaction of a compound (IX) with a metallated (e.g. lithiated) derivative of acetonitrile; they may also be prepared indirectly by reaction with a metallated derivative of an ester of acetic acid, followed by conversion of the ester group to a carboxamide group and then to a nitrile group, e.g. as described above.

In general compounds (I) and starting materials therefor in which Y is substituted by a hydroxyl group may be converted to corresponding ether and ester derivatives by standard methods such as are well known in the art. Thus, for example, etherification may be effected by reaction with an appropriate organic halide (e.g. an alkyl iodide) in the presence of an appropriate base (e.g. an alkali metal alkoxide such as potassium t-butoxide), advantageously in the presence of a crown ether such as 18-crown-6. Esterification may be effected by reaction with appropriate acylating agents, such as acyl halides, acid anhydrides and the like.

Compounds of formula (VII) may be prepared from estrone, equilinenin or equilin as appropriate by, for example, Wittig reaction with an ethylidene phosphorane

to convert the 17-one to the corresponding Z-17(20) ethylidene compound, following the procedure described by Krubiner and Oliveto, J. Org. Chem. 31, pp. 24-26 [1965]. Alternatively, the corresponding E-isomer may be obtained following the procedure of Midland and Kwon, Tetrahedron Lett. 23(20), pp. 2077-2080 [1982]. The thus-obtained alkenes may be subjected to conventional stereospecific hydroboration reactions followed by oxidative work-up with alkaline hydrogen peroxide solution (Krubiner, *op. cit.*) to afford the corresponding 20-ols, which may be oxidised to 20-ones with chromium trioxide (Krubiner, *op. cit.*). Wittig reaction with methoxymethylenetriphenylphosphorane, hydrolysis of the enol ether with aqueous acid (to give a non-stereospecific aldehyde of formula (IX) in which Y^b represents a valence bond), reduction with sodium borohydride and reaction of the resulting alcohol with tosyl chloride affords compounds of formula (VII) wherein R^3 is methyl, Y^a is methylene and L is tosyloxy.

Compounds of formula (VII) having a double bond at the 16(17)-position may, for example, be prepared stereospecifically by subjecting the appropriate E- or Z-17(20) ethylidene compound prepared as described above to a stereospecific ene reaction. For example, such ene reactions include treatment with formaldehyde, boron trifluoride and optionally acetic anhydride (Batcho et al., Helv. Chim. Acta 64, pp. 1682-1687 [1981]) to form compounds of formula (VII) in which R^3 is methyl, Y^a is methylene and L is hydroxy or acetoxy. The acetyl group may be removed by hydrolysis and the hydroxyl group may be tosylated to generate a compound (VII) in which L is a suitable leaving group. In an alternative ene reaction, treatment with ethyl propiolate/diethyl aluminium chloride (Dauben and Brookhart, J. Am. Chem. Soc. 103, pp. 237-238 [1980]) affords ethyl esters of $\Delta^{16,17}$ acids of general formula (XI) in which R^3 is methyl and Y is ethylene, from which the corresponding

- 20 -

free acid may be obtained by hydrolysis. The $\Delta_{16,17}$ compounds described above may be stereospecifically hydrogenated.

Compounds of formula (VII) in which Y^a is e.g.

5 ethylene or trimethylene may, for example, be obtained by reaction of a compound (VII) in which Y^a is methylene either (i) with a reagent serving to introduce a one-carbon fragment (e.g. a metal cyanide) and conversion of the group so introduced to a group $-CH_2L$, e.g. by
10 hydrolysing a cyano group to yield a carboxy group or by reducing such a cyano group (e.g. with a metal hydride reducing agent such as diisobutyl aluminium hydride) to yield a carboxaldehyde group, and reducing the carboxy or carboxaldehyde group (e.g. using sodium borohydride or lithium aluminium hydride) to yield a hydroxymethyl
15 group which may in turn be subjected to tosylation and, if desired, nucleophilic displacement as hereinbefore described to effect conversion to a halomethyl group; or (ii) with a metallated derivative of an ester or
20 thioester of acetic acid, with a derivative containing another carbanionic equivalent of acetic acid (e.g. a metallated derivative of acetonitrile), or with a metallated malonate ester (in which last instance the reaction product is partially hydrolysed to yield a
25 monoester which may be decarboxylated by heating to yield a carboxylate ester), reducing the resulting ester or thioester product to an alcohol (e.g. using lithium aluminium hydride), and converting the resulting hydroxyl group to a leaving group, such as a tosylate
30 group or a halogen atom, e.g. as hereinbefore described.

It will be appreciated that the above procedures (i) and/or (ii) may be repeated as needed to yield compounds (VII) in which Y^a is a C_{3-7} alkylene group.

In general, O-protecting groups may, for example,
35 be removed by conventional methods such as are well documented in the literature. Thus esterifying acyl groups may be removed by basic hydrolysis, e.g. using an

- 21 -

alkali metal alkoxide in an alkanol. Etherifying groups such as silyl groups may be removed by acid hydrolysis or treatment with a fluoride salt, e.g. a tetraalkyl ammonium fluoride. The use of such acid-labile but

5 base-stable protecting groups may be of particular advantage during homologation steps to build up a desired side chain, in view of the strongly basic conditions normally employed for such reactions.

10 The following non-limitative examples serve to illustrate the invention. All temperatures are in °C.

Preparation 1

- 5 a) 3-Triisopropylsilyloxy-19-nor-chol-1,3,5(10),16-tetraen-24-ol [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $Y^a = (\text{CH}_2)_3$, $L = \text{OH}$, $\Delta 16$ double bond]

10 A solution of 3-triisopropylsilyloxy-19-nor-chol-1,3,5(10),16,22-pentaene-24-carboxylic acid methyl ester [Formula (VII) - $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $Y^a = \text{-CH=CH-}$, $L = \text{CO.OCH}_3$, $\Delta 16$ double bond] (177 mg - prepared by
15 silylation of the corresponding 3-hydroxy compound) in ether (6.5 ml) was added dropwise to a solution of lithium aluminium hydride in ether (3 ml of a 1M solution). The mixture was stirred for 3 hours and
15 worked up to afford the title compound as an approximately 85/15 mixture with the corresponding $\Delta 22$ compound.

- 20 b) 3-Triisopropylsilyloxy-19-nor-chol-1,3,5(10),16-tetraen-24-ol, 24-tosylate [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $Y^a = (\text{CH}_2)_3$, $L = \text{O.SO}_2\text{.C}_6\text{H}_4\text{.CH}_3$, $\Delta 16$ double bond]

25 A solution containing the mixture of alcohols from (a) above (223 mg), tosyl chloride (216 mg) and pyridine (476 μl) in methylene chloride (4 ml) was stirred at room temperature for 4 hours, treated with aqueous sodium bicarbonate solution, stirred overnight, and
30 worked up to afford a mixture of the $\Delta 22$ alcohol and the title compound (190 mg): NMR (CDCl_3) δ 0.85 (s, 18-H's), 2.65 (s, tosyl-Me), 3.9 (t, 24-H's), 5.1 (bs, 16-H), 6.5 and 6.95 (m, 1-, 2- and 4-H's), 7.65 and 7.62 (ABq, tosyl-H's).

- 23 -

c) 3-Triisopropylsilyloxy-19-nor-chol-1,3,5(10),16-tetraene-24-bromide [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (i\text{-Pr})_3\text{Si}$, $R^5 = \text{H}$, $Y^a = (\text{CH}_2)_3$, $L = \text{Br}$, $\Delta 16$ double bond]

5 The 24-tosylate from (b) above (190 mg) in 1,2-dichloroethane (5 ml) and acetonitrile (5 ml) containing lithium bromide (300 mg) was heated under reflux for 3 hours. The reaction mixture was then cooled, diluted with ethyl acetate, washed with water then brine, and
10 dried over sodium sulphate. Evaporation of the solvent gave the title compound (156 mg): NMR (CDCl_3) δ 0.9 (s, 18-H's), 3.5 (t, 24-H's), 5.2 (bs, 16-H), 6.5 and 6.95 (m, 1-, 2- and 4-H's).

15 Preparation 2

a) 3-Triisopropylsilyloxy-19-nor-chol-1,3,5(10)-triene-24-carboxylic acid methyl ester [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (i\text{-Pr})_3\text{Si}$, $R^5 = \text{H}$, $Y^a = (\text{CH}_2)_2$, $L = \text{CO.OCH}_3$]

20

A solution of the $\Delta 16$, $\Delta 22$ -pentaenic acid methyl ester used as starting material in Preparation 1(a) (200 mg) in ethyl acetate (10 ml) was treated with
25 palladium/charcoal (400 mg, 10%) and stirred overnight under an atmosphere of hydrogen. Filtration through Celite and removal of the solvent under reduced pressure afforded the title compound (177 mg): NMR (CDCl_3) δ 0.96 (s, 18-H's), 3.7 (s, ester CH_3), 6.5 and 6.95 (m, 1-, 2- and 4-H's) (peaks at δ 5.2 and 5.6-5.9 were absent).
30

b) 3-Triisopropylsilyloxy-19-nor-chol-1,3,5(10)-trien-24-ol [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (i\text{-Pr})_3\text{Si}$, $R^5 = \text{H}$, $Y^a = (\text{CH}_2)_3$, $L = \text{OH}$]

35

The ester from (a) above (177 mg) was treated with lithium aluminium hydride (3 ml of a 1M solution in

- 24 -

ether) for 3 hours at room temperature. The resulting product was worked up to give the title compound (158 mg): NMR (CDCl_3) δ 3.9 (t, 24-H's), 6.5 and 6.95 (m, 1-, 2- and 4-H's) (peak at δ 3.8 was absent).

5

c) 3-Triisopropylsilyloxy-19-nor-chol-1,3,5(10), triene-24-bromide [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (i\text{-Pr})_3\text{Si}$, $R^5 = \text{H}$, $Y^a = (\text{CH}_2)_3$, $L = \text{Br}$]

10 Treatment of the alcohol from (b) above (158 mg) with tosyl chloride as in Preparation 1(b), followed by treatment of the resulting toluene sulphonate (176 mg) with lithium bromide as in Preparation 1(c) afforded the title compound (131 mg): NMR (CDCl_3) δ 0.96 (s, 18-H's),
15 3.4 (t, 24-H's), 6.5 and 6.95 (m, 1-, 2- and 4-H's).

Preparation 3

a) 3-Triisopropylsilyloxy-20 α -acetoxymethyl-19-nor-pregn-1,3,5(10),16-tetraene [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (i\text{-Pr})_3\text{Si}$, $R^5 = \text{H}$, $Y^a = \text{CH}_2$, $L = \text{O.CO.CH}_3$, Δ^{16} double bond]

25 A mixture of boron trifluoride etherate (50 μl) and acetic anhydride (0.6 ml) in dichloromethane (0.6 ml) was added dropwise to a solution of 3-triisopropylsilyloxy-19-nor-pregn-1,3,5(10),17(20)Z-tetraene (1.8 g) in dichloromethane (2 ml) containing acetic anhydride (0.9 ml) and paraformaldehyde (120 mg). The mixture was
30 stirred for 2 hours, whereafter saturated sodium hydrogen carbonate was added and stirring was continued for 2 hours. The product was isolated by extraction into dichloromethane and purified by chromatography to give the title compound (1.5 g).

35

b) 3-Triisopropylsilyloxy-20 α -hydroxymethyl-19-nor-pregn-1,3,5(10)-triene [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (i\text{-Pr})_3\text{Si}$, $R^5 = \text{H}$, $Y^a = \text{CH}_2$, $L = \text{OH}$, $\Delta 16$ double bond]

5 A solution of the product from (a) above (1.2 g) in ethanol (20 ml) containing 5% platinum on carbon (240 mg) was stirred under hydrogen for 2 days. Filtration and removal of the solvent afforded the 20-acetate of the title product (1.15 g), 480 mg of which was reduced
10 with lithium aluminium hydride (1.2 ml of 1 M solution in ether) in ether (10 ml) to give the title compound (440 mg): IR (CDCl_3) ν_{max} 1600, 3280 cm^{-1} ; NMR (CDCl_3) δ 0.7 (s, 18-H's), 6.3-7.2 (m, 1-, 2- and 4-H's).

15 c) 3-Triisopropylsilyloxy-20 α -tosyloxymethyl-19-nor-pregn-1,3,5(10)-triene [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (i\text{-Pr})_3\text{Si}$, $R^5 = \text{H}$, $Y^a = \text{CH}_2$, $L = \text{O}\cdot\text{SO}_2\cdot\text{C}_6\text{H}_4\cdot\text{CH}_3$]

A solution of the alcohol from step (b) above (440 mg)
20 in dichloromethane (2 ml) containing pyridine (0.5 ml) and tosyl chloride (445 mg) was stirred at room temperature overnight. The reaction mixture was then treated with aqueous sodium hydrogen carbonate and stirred for a further 2 hours, whereafter the product
25 was extracted into dichloromethane and the extract was washed successively with water, 3% phosphoric acid and brine. Removal of the solvent followed by chromatography gave the title compound (485 mg): IR (CDCl_3) ν_{max} 1600 cm^{-1} ; NMR (CDCl_3) δ 0.66 (s, 18-H's),
30 2.33 (s, tosyl-Me), 3.5-4.2 (bm, 22-H's), 6.3-7.0 (m, 1-, 2- and 4-H's), 7.0, 7.9 (m, tosyl aryl-H's).

d) 3-Triisopropylsilyloxy-20 α -bromomethyl-19-nor-pregn-1,3,5(10)-triene [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (i\text{-Pr})_3\text{Si}$, $R^5 = \text{H}$, $Y^a = \text{CH}_2$, $L = \text{Br}$]

The tosylate from step (c) above (485 mg) in a mixture

- 26 -

of acetonitrile (16 ml) and dichloroethane (16 ml) containing lithium bromide (654 mg) was stirred overnight; water was then added and the product was extracted into dichloroethane. The extract was washed and dried, and the solvent was removed to give the title compound (360 mg). This product was used in further steps without further purification.

Preparation 4

3-Triisopropylsilyloxy-20 α -formyl-19-nor-pregn-1,3,5(10)-triene [Formula (IX): R³ = α -CH₃, R⁴ = (i-Pr)₃Si, R⁵ = H, Y^b = valence bond]

The 20-hydroxymethyl compound from Preparation 3(b) (220 mg) was stirred with pyridinium dichromate (1.25 mmol) in dichloromethane (3 ml) for 2 hours. Residual reagent was filtered off, the solvent was removed and the resulting material was purified by preparative thin layer chromatography (PTLC) to give the title compound (120 mg): IR (CDCl₃) ν_{\max} 1600, 1710 cm⁻¹; NMR (CDCl₃) δ 0.7 (s, 18-H's), 6.3-7.2 (m, 1-, 2- and 4-H's), 9.3, 9.5 (d, CHO).

Preparation 5

2-Methoxy-3-triisopropylsilyloxy-19-nor-pregn-1,3,5(10), 17(20)Z-tetraene

Sodium hydride (294 mg, 50%) in dimethylsulphoxide (6 ml) was stirred at 70°C for 1 hour, then cooled to room temperature. Ethyltriphenylphosphonium iodide (2.75 g) in dimethylsulphoxide (10 ml) was added dropwise and the resulting mixture was stirred for 30 minutes. A solution of 2-methoxy-estrone-3-triisopropylsilyl ether (600 mg, prepared by silylation of the 3-OH compound with triisopropylsilyl chloride and imidazole in

- 27 -

dichloromethane overnight at room temperature) in dimethylsulphoxide (10 ml) was added dropwise. The resulting solution was stirred for 30 minutes, whereafter the temperature was raised to 70° and stirring was continued overnight. The reaction mixture was cooled and worked up. Separation and purification of the products by chromatography gave the title compound (125 mg, see below) and the 3-OH analogue (300 mg): IR (CDCl₃) ν_{\max} 1590, 3520 cm⁻¹; NMR (CDCl₃) δ 0.9 (s, 18-H's), 1.67 (d, =CH-CH's), 3.8 (s, OCH's), 4.7-5.2 (q, =CHMe), 6.5, 6.7 (s, 1,4-H's).

Silylation of this 3-OH compound (300 mg) as above and purification of the product by chromatography gave the title compound (370 mg): IR (CDCl₃) ν_{\max} 1600 cm⁻¹; NMR (CDCl₃) δ 0.9 (s, 18-H's), 1.68 (d, =CH-CH's), 3.7 (s, OCH's), 4.7-5.3 (q, =CH-Me), 6.4, 6.6 (s, 1,4-H's).

Preparation 6

a) 2-Methoxy-3-triisopropylsilyloxy-19-nor-chol-1,3,5(10),16-tetraene-24-carboxylic acid methyl ester
[Formula (VI): R³ = α -CH₃, R⁴ = (i-Pr)₃Si, R⁵ = OCH₃, R⁹ = CH₃, Y = (CH₂)₂, Δ 16 double bond]

Ethyl aluminium dichloride (1.4 ml, 2.4mmol, in toluene) was added dropwise to a solution of the product from Preparation 5 (370 mg) in dichloromethane (4 ml) containing methyl acrylate (144 μ l). The resulting mixture was stirred for 4 hours, whereafter further methyl acrylate (144 μ l) was added and stirring was continued overnight. The reaction mixture was then worked up and the product was purified by chromatography to give the title compound (345 mg): IR (CDCl₃) ν_{\max} 1600, 1720 cm⁻¹; NMR (CDCl₃) δ 0.8 (s, 18-H's), 3.6 (s, OCH's), 5.1-5.4 (bs, 16-H's), 6.4, 6.58 (s, 1,4-H's).

b) 2-Methoxy-3-triisopropylsilyloxy-19-nor-chol-1,3,5(10),16-tetraen-24-ol [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (i\text{-Pr})_3\text{Si}$, $R^5 = \text{OCH}_3$, $L = \text{OH}$, $Y^a = (\text{CH}_2)_3$, Δ_{16} double bond]

Lithium aluminium hydride (1 ml of a 1 M solution in ether) was added dropwise to a solution of the ester from (a) above (265 mg) in ether (5 ml), whereafter the reaction mixture was stirred for 30 minutes, diluted with ether and quenched with wet sodium sulphate, giving crude title compound (248 mg): IR (CDCl_3) ν_{max} 1600, 3380-3660 cm^{-1} ; NMR (CDCl_3) δ 0.8 (s, 18-H's), 3.3-3.8 (b, HOCH's), 3.7 (s, OCH's), 5.1-5.4 (bs, 16-H's), 6.4, 6.6 (s, 1,4-H's).

c) 2-Methoxy-3-triisopropylsilyloxy-19-nor-chol-1,3,5(10),16-tetraen-24-ol, 24-tosylate [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (i\text{-Pr})_3\text{Si}$, $R^5 = \text{OCH}_3$, $L = \text{O}\cdot\text{SO}_2\cdot\text{C}_6\text{H}_4\cdot\text{CH}_3$, $Y^a = (\text{CH}_2)_3$, Δ_{16} double bond]

A solution of the alcohol from (b) above (248 mg) in dichloromethane (4 ml) containing tosyl chloride (290 mg) and pyridine (250 μl) was stirred overnight. Work up and purification by chromatography gave the title compound (245 mg): IR (CDCl_3) ν_{max} 1595 cm^{-1} ; NMR (CDCl_3) δ 0.7 (s, 18-H's), 2.4 (s, tosyl-Me), 3.8-4.1 (b, TsOCH's), 3.7 (s, OCH's), 5.0-5.3 (bs, 16-H's), 6.4, 6.56 (s, 1,4-H's), 7.0-7.8 (ABq, tosyl arH's).

d) 2-Methoxy-3-triisopropylsilyloxy-19-nor-chol-1,3,5(10),16-tetraene-24-bromide [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (i\text{-Pr})_3\text{Si}$, $R^5 = \text{OCH}_3$, $L = \text{Br}$, $Y^a = (\text{CH}_2)_3$, Δ_{16} double bond]

The tosylate from (c) above (245 mg) was dissolved in dichloroethane (6 ml) and acetonitrile (6 ml) containing lithium bromide (310 mg) and the resulting mixture was

- 29 -

heated under reflux for 3 hours. The mixture was worked up and the product was purified by chromatography to give the title compound (200 mg): IR (CDCl₃) ν_{\max} 1600 cm⁻¹; NMR (CDCl₃) δ 0.83 (s, 18-H's), 3.2-3.5 (b, BrCH's), 3.73 (s, OCH's), 5.1-5.4 (bs, 16-H's), 6.43, 6.56 (s, 1,4-H's).

e) 2-Methoxy-3-triisopropylsilyloxy-20 α -formyl-19-nor-pregn-1,3,5(10)-triene [Formula (IX): R³ = α -CH₃, R⁴ = (i-Pr)₃Si, R⁵ = OCH₃, Y^b = valence bond]

This is prepared from the product of Preparation 5 according to the procedures of Preparations 3(a), 3(b) and 4.

f) 2-Methoxy-3-triisopropylsilyloxy-20 α -bromomethyl-19-nor-pregn-1,3,5(10)-triene [Formula (VII): R³ = α -CH₃, R⁴ = (i-Pr)₃Si, R⁵ = OCH₃, Y^a = CH₂, L = Br]

This is prepared from the product of Preparation 5 according to the procedures of Preparations 3(a)-(d).

Preparation 7

a) 3-Triisopropylsilyloxy-19-nor-pregn-1,3,5(10),6,8,17(20)Z-hexaene

3-Hydroxy-19-nor-androst-1,3,5(10),6,8 pentaen-17-one was subjected to a Wittig reaction followed by silylation as in Preparation 5 to give the title compound: IR (CDCl₃) ν_{\max} 1590, 1610 cm⁻¹; NMR (CDCl₃) δ 0.73 (s, 18-H's), 1.73 (d, =CH-CH's), 4.8- 5.5 (q, =CH-Me), 6.7, 8.0 (s, 1-, 2-, 4-, 6- and 7-H's).

- 30 -

b) 3-Triisopropylsilyloxy-19-nor-chol-1,3,5(10), 6,8,16-hexaene-24-carboxylic acid methyl ester [Formula (VI): $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $R^9 = \text{CH}_3$, $Y = (\text{CH}_2)_2$, $\Delta 6$, $\Delta 8$ and $\Delta 16$ double bonds]

5

The product from (a) above was subjected to an ene reaction as in Preparation 6(a) to give the title compound: IR (CDCl_3) ν_{max} 1590, 1610, 1725 cm^{-1} ; NMR (CDCl_3) δ 0.67 (s, 18-H's), 0.82 (d, 21-H's), 2.9-3.5 (bm, 23-H's), 3.63 (s, COOCH 's), 5.2-5.6 (bs, 16-H's), 6.7, 8.0 (s, 1-, 2-, 4-, 6- and 7-H's).

10

c) 3-Triisopropylsilyloxy-19-nor-chol-1,3,5(10), 6,8,16-hexaen-24-ol [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $L = \text{OH}$, $Y^a = (\text{CH}_2)_3$, $\Delta 6$, $\Delta 8$ and $\Delta 16$ double bonds]

15

The product from (b) above was reacted as in Preparation 6(b) to give the title compound: IR (CDCl_3) ν_{max} 1590, 1600, 3360-3660 cm^{-1} ; NMR (CDCl_3) δ 0.66 (s, 18-H's), 0.82 (d, 21-H's), 3.4-3.9 (b, HOCH 's), 5.2-5.5 (bs, 16-H's), 6.8-8.0 (s, 1-, 2-, 4-, 6- and 7-H's).

20

d) 3-Triisopropylsilyloxy-19-nor-chol-1,3,5(10), 6,8,16-tetraen-24-ol, 24-tosylate [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $L = \text{O.SO}_2.\text{C}_6\text{H}_4.\text{CH}_3$, $Y^a = (\text{CH}_2)_3$, $\Delta 6$, $\Delta 8$ and $\Delta 16$ double bonds]

25

The product from (c) above was reacted as in Preparation 6(c) to give the title compound: IR (CDCl_3) ν_{max} 1590, 1610 cm^{-1} ; NMR (CDCl_3) δ 0.6 (s, 18-H's), 0.78 (d, 21-H's), 2.4 (s, tosyl-Me), 3.8-4.3 (b, TsOCH 's), 5.2-5.5 (bs, 16-H's), 6.8-8.1 (m, 1-, 2-, 4- and tosyl arH's).

30

35

- 31 -

e) 3-Triisopropylsilyloxy-19-nor-chol-1,3,5(10),6,8,16-hexaene-24-bromide [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{OCH}_3$, $L = \text{Br}$, $Y^a = (\text{CH}_2)_3$, $\Delta 6$, $\Delta 8$ and $\Delta 16$ double bonds]

5

This was prepared by reacting the tosylate from (d) above according to the method of Preparation 6(d) to give the title compound: IR (CDCl_3) ν_{max} 1590, 1600 cm^{-1} ; NMR (CDCl_3) δ 0.66 (s, 18-H's), 5.2-5.5 (bs, 16-H's), 6.8-8.0 (m, 1-, 2-, 4-, 6- and 7-H's).

10

Preparation 8

a) 3-Tetrahydropyranyloxy-19-nor-pregn-1,3,5(10),17(20)E-tetraene-21-carboxylic acid ethyl ester

15

A solution of estrone-3-tetrahydropyranyl ether (1.25 g, prepared according to J. Chem. Soc. Perkin, pp. 1282-1286, [1978]) in ethanol (18 ml) containing diethyl ethoxycarbonylmethylphosphonate (2.65 ml) was treated with sodium ethoxide (6.75 ml of a 21% solution in ethanol) and heated under reflux for 15 hours. After work up the product was purified by chromatography to afford the title compound (1.12 g): IR (CDCl_3) ν_{max} 1450-1600, 1645, 1695 cm^{-1} ; NMR (CDCl_3) δ 0.8 (s, 18-H's), 3.55 (m, six H's of THP), 4.05 (q, COOCH 's), 5.25 (m, two H's of THP), 5.45 (20-H), 6.7-7.05 (m, 1-, 2- and 4-H's).

20

25

30

b) 3-Tetrahydropyranyloxy-19-nor-pregn-1,3,5(10),17(20)E-tetraen-21-ol

Lithium aluminium hydride (4.9 ml of a 1 M solution in ether) was added to a solution of the ester from (a) above (1 g) in ether (4 ml). After 4 hours the reaction was quenched with wet sodium sulphate, the reaction mixture was worked up and the solvent was removed to

35

- 32 -

give the title compound (0.9 g): IR (CDCl₃) ν_{\max} 1610, 3580 cm⁻¹; NMR (CDCl₃) δ 0.76 (s, 18-H's), 3.35 (m, six H's of THP), 3.95 (d, 21-H's), 5.25 (m, two H's of THP), 5.1 (20-H), 6.7-7.05 (m, 1-, 2- and 4-H's).

5

c) 3-Triisopropylsilyloxy-19-nor-pregn-1,3,5(10), 17(20)E-tetraene

10 A solution of the alcohol from (b) above (0.9 g) in tetrahydrofuran (10 ml) at 0° was treated with pyridinium sulphate (576 mg). The resulting mixture was stirred for 4 hours, whereafter lithium aluminium
15 hydride (9.6 ml of a 1M solution in tetrahydrofuran) was added and stirring was continued for 1 hour at 0° and then at room temperature overnight. The crude product (0.7 g), containing a mixture of the 3-OH compound and the 3-THP ether, was cleaved by storage overnight in acetone (15 ml) containing p-toluenesulphonic acid (150 mg of hydrate). The cleaved 3-OH product (700 mg) was
20 silylated by treatment with chlorotriisopropylsilane (623 μ l) in dichloromethane (3 ml) containing imidazole (720 mg) at room temperature overnight, and following work up gave the title compound (800 mg): IR (CDCl₃) ν_{\max} 1610, 1600-1450 (three bands) cm⁻¹; NMR (CDCl₃) δ 0.78
25 (s, 18-H's), 1.05-1.2 (silyl H's), 1.50 (d, 21-H's), 5.0 (q, 20-H), 6.5-6.95 (m, 1-, 2- and 4-H's).

d) 3-Triisopropylsilyloxy-20-epi-19-nor-chol-1,3,5(10),16,22-pentaene-24-carboxylic acid methyl ester
30 [Formula (VI): R³ = β -CH₃, R⁴ = (i-Pr)₃Si, R⁵ = H, R⁰ = CH₃, Y = CH=CH, Δ 16 double bond]

A solution of the E-alkene from (c) above (800 mg) in benzene was treated with diethyl aluminium chloride
35 (3.19 ml) and methyl propiolate (0.415 ml) and stirred for 3 days. The reaction mixture was then worked up and the product was purified by chromatography to give the

- 33 -

title compound: IR (CDCl₃) ν_{\max} 1640, 1710 cm⁻¹; NMR (CDCl₃) δ 0.78 (s, 18-H's), 3.5 (s, OCH's), 4.0 (by product), 5.2 (t, 16-H's), 6.5, 6.95 (s, 1-, 2- and 4-H's).

5

e) 3-Triisopropylsilyloxy-20-epi-19-nor-chol-1,3,5(10),16-tetraen-24-ol [Formula (VII): R³ = β -CH₃, R⁴ = (i-Pr)₃Si, R⁵ = H, L = OH, Y^a = (CH₂)₃, Δ 16 double bond]

10 Treatment of the ester from (d) above (400 mg) with lithium aluminium hydride according to the method of Preparation 6(b) (except with inverse addition) and work up gave the title compound (360 mg, mixed with the 22,23 unsaturated alcohol in a ratio of approximately 85:15):
15 IR (CDCl₃) ν_{\max} 1600, 3580 cm⁻¹; NMR (CDCl₃) δ 0.78 (s, 18-CH's), 3.5 (m, HOCH's), 3.7 (s, OCH's), 5.1-5.4 (bs, 16-H's), 6.4, 6.6 (s, 1-, 2- and 4-H's).

f) 3-Triisopropylsilyloxy-20-epi-19-nor-chol-1,3,5(10),16-tetraen-24-ol, 24-tosylate [Formula (VII): R³ = β -CH₃, R⁴ = (i-Pr)₃Si, R⁵ = H, L = O.SO₂.C₆H₄.CH₃, Y^a = (CH₂)₃, Δ 16 double bond]

20 The alcohol from (e) above (360 mg) was tosylated as in Preparation 6(c). The desired product was separated from the "unreacted" 22,23 unsaturated alcohol by chromatography to give the title compound (380 mg): NMR (CDCl₃) δ 0.78 (s, 18-H's), 2.4 (s, tosyl-Me), 3.95 (t, TsOCH's), 5.15 (bs, 16-H's), 6.4, 6.95 (s, 1,4-H's),
25 7.2-7.7 (ABq, tosyl arH's).
30

g) 3-Triisopropylsilyloxy-20-epi-19-nor-chol-1,3,5(10),16-tetraene-24-bromide [Formula (VII): R³ = β -CH₃, R⁴ = (i-Pr)₃Si, R⁵ = H, L = Br, Y^a = (CH₂)₃, Δ 16 double bond]

35

The tosylate from (f) above (500 mg) was dissolved in a

- 34 -

mixture of dichloroethane (13 ml) and acetonitrile (13 ml) containing lithium bromide (700 mg) and the resulting mixture was heated under reflux for 3.5 hours. The mixture was then worked up and the product was purified by chromatography to give the title compound (350 mg): NMR (CDCl₃) δ 0.78 (s, 18-H's), 3.35 (b, BrCH's), 5.25 (bs, 16-H's), 6.5, 6.95 (s, 1,4-H's).

h) 3-Triisopropylsilyloxy-20 β -formyl-19-nor-pregna-1,3,5(10)-triene [Formula (IX): R³ = β -CH₃, R⁴ = (i-Pr)₃Si, R⁵ = H, Y^b = valence bond]

This is prepared from the product of Preparation 8(c) according to the procedures of Preparations 3(a), 3(b) and 4.

i) 3-Triisopropylsilyloxy-20 β -bromomethyl-19-nor-pregna-1,3,5(10)-triene [Formula (VII): R³ = β -CH₃, R⁴ = (i-Pr)₃Si, R⁵ = H, Y^a = CH₂, L = Br]

This is prepared from the product of Preparation 8(c) according to the procedures of Preparations 3(a)-(d).

Preparation 9

a) 3-Triisopropylsilyloxy-19-nor-pregna-1,3,5(10), 8,17(20)Z-pentaene

3-Hydroxy-19-nor-androst-1,3,5(10),8-tetraen-17-one was subjected to a Wittig reaction followed by silylation as in Preparation 5 to give the title compound: IR (CDCl₃) ν_{\max} 1600 cm⁻¹; NMR (CDCl₃) δ 0.8 (s, 18-H's), 4.8-5.4 (b, =CH-Me, 8H), 6.7-7.3 (m, 1-, 2- and 4-H's).

b) 3-Triisopropylsilyloxy-19-nor-chol-1,3,5(10),6,16-pentaene-24-carboxylic acid methyl ester [Formula (VI): $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $R^9 = \text{CH}_3$, $Y = (\text{CH}_2)_2$, $\Delta 6$ and $\Delta 16$ double bonds]

5

The product from (a) above was subjected to an ene reaction as in Preparation 6(a) to give the title compound: IR (CDCl_3) ν_{max} 1590, 1610, 1725 cm^{-1} ; NMR (CDCl_3) δ 0.67 (s, 18-CH's), 3.8-4.3 (q, $\text{COOCH}'\text{s}$), 5.2-5.6 (bs, 16-H's), 6.8-8.0 (s, 1-, 2-, 4- and 6-H's).

10

c) 3-Triisopropylsilyloxy-19-nor-chol-1,3,5(10),6,16-pentaen-24-ol [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $L = \text{OH}$, $Y^a = (\text{CH}_2)_3$, $\Delta 6$ and $\Delta 16$ double bonds]

15

Reaction of the product from (b) above as in Preparation 6(b) gave the title compound: IR (CDCl_3) ν_{max} 1595, 1620, 3300-3640 cm^{-1} ; NMR (CDCl_3) δ 0.7 (s, 18-CH's), 3.3-3.8 (b, $\text{HOCH}'\text{s}$), 5.1-5.5 (b, 16-H's), 6.8-7.9 (s, 1-, 2-, 4- and 6-H's).

20

d) 3-Triisopropylsilyloxy-19-nor-chol-1,3,5(10),6,16-pentaen-24-ol, 24-tosylate [Formula (VII): $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $L = \text{O}.\text{SO}_2.\text{C}_6\text{H}_4.\text{CH}_3$, $Y^a = (\text{CH}_2)_3$, $\Delta 6$ and $\Delta 16$ double bonds]

25

Reaction of the product from (c) above as in Preparation 6(c) gave the title compound: IR (CDCl_3) ν_{max} 1590, 1625 cm^{-1} ; NMR (CDCl_3) δ 0.6 (s, 18-CH's), 2.37 (s, tosyl-Me), 3.7-4.2 (b, $\text{TsOCH}'\text{s}$), 5.1-5.5 (b, 16-H's), 6.7-7.9 (m, 1-, 2-, 4-, 6- and tosyl arH's).

30

206250 16492660

e) 3-Triisopropylsilyloxy-19-nor-chole-1,3,5(10),6,16-
pentaene-24-bromide [Formula (V): $R^3 = \alpha\text{-CH}_3$, $R^4 =$
(i-Pr) $_3$ Si, $R^5 = \text{H}$, L = Br, $\text{Y}^a = (\text{CH}_2)_3$, $\Delta 6$ and $\Delta 16$ double
bonds]

Reaction of the tosylate from (d) above according to the method of Preparation 6(d) gave the title compound: IR (CDCl₃) ν_{\max} 1585, 1610 cm⁻¹; NMR (CDCl₃) δ 0.63 (s, 18-H's), 5.1-5.5 (b, 16-H's), 6.7-7.9 (m, 1-, 2-, 4- and 6-H's).

Example 1

a) 3-Triisopropylsilyloxy-23,23a-bishomo-19-nor-chole-
1,3,5(10)16-tetraene-24-nitrile [Formula (II): R³ = α -
CH₃, R⁴ = (i-Pr)₃Si, R⁵ = H, Y = (CH₂)₄, Δ 16 double bond]

A solution of acetonitrile (0.16 ml) in tetrahydrofuran (1.5 ml) was added dropwise at -78° to a solution of butyl lithium in hexane (3 mM in 1.9 ml) and the reaction mixture was stirred for 50 minutes. The bromide from Preparation 1(c) (150 mg) in tetrahydrofuran (3 ml + 1 ml wash) was added and the mixture was stirred for a further hour then warmed to -30° for an hour. TLC indicated the absence of starting material, so the mixture was cooled to -78° and treated with ammonium chloride. The product was extracted into ether and worked up to afford the title compound (85 mg): IR ν_{\max} 2250, 1620 cm^{-1} ; NMR (CDCl_3) δ 0.96 (s, 18-H's), 5.2 (bs, 16-H), 6.5 and 6.95 (m, 1-, 2- and 4-H's).

- 37 -

b) 25-Amino-3-triisopropylsilyloxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \alpha-CH_3$, $R^4 = (i-Pr)_3Si$, $R^5 = H$, $X = NH_2$, $Y = (CH_2)_4$, $\Delta 16$ double bond]

5

Anhydrous cerous chloride was prepared by heating $CeCl_3 \cdot 7H_2O$ (2 g) in vacuo (<0.1 mm Hg) first at 70° for 1 hour, then at 110° for 1 hour and finally at 145° for 2½ hours. Thus-obtained anhydrous cerous chloride (256 mg) was heated in vacuo at 130° for 2 hours, cooled, then suspended in tetrahydrofuran (3 ml); the resulting mixture was kept overnight with stirring. The suspension was cooled to -78° and then treated with methyl lithium (0.86 ml of a 1.4 M solution in ether). The mixture was stirred for 15 minutes at -78°, 15 minutes at 0°, then cooled to -78° and the nitrile from (a) above (84 mg) in tetrahydrofuran (2 ml + 1 ml wash) was added dropwise. After a further hour at -78° (TLC control), ammonium hydroxide was added and the mixture was warmed to room temperature and filtered through Celite (methylene chloride wash). Removal of the solvents gave the title compound (67 mg, isolated by chromatography): IR ν_{max} 1620 cm^{-1} ; NMR ($CDCl_3$) δ 0.96 (s, 18-H's), 0.99 (21-H's), 1.25 (25-H's), 5.2 (bs, 16-H), 6.5 and 6.95 (m, 1-, 2- and 4-H's).

10

15

20

25

c) 25-Acetylamino-3-triisopropylsilyloxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \alpha-CH_3$, $R^4 = (i-Pr)_3Si$, $R^5 = H$, $X = NH(COCH_3)$, $Y = -(CH_2)_4$, $\Delta 16$ double bond]

30

The amine from (b) above (67 mg) in dichloromethane (2 ml) containing pyridine (0.475 ml) and acetic anhydride (0.475 ml) was stirred for 4 hours, whereafter the mixture was diluted with dichloromethane, treated with aqueous sodium bicarbonate, and stirred overnight. Work up afforded the title compound (70 mg, isolated by

35

- 38 -

preparative TLC): IR ν_{\max} 1690, 1620, 1600-1450 cm^{-1} ; NMR (CDCl_3) δ 0.96 (s, 18-H's), 0.99 (21-H's), 1.25 (25-H's), 1.9 (s, COCH's) 5.0 (s, NH), 5.15 (bs, 16-H), 6.5 and 6.95 (m, 1-, 2- and 4-H's).

5

d) 25-Acetylamino-3-hydroxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = \text{CH}_3$, $R^3 = \alpha\text{-CH}_3$, $R^4 = R^5 = \text{H}$, $X = \text{NH}(\text{COCH}_3)$, $Y = (\text{CH}_2)_4$, $\Delta 16$ double bond]

10

The silyl compound from (c) above (70 mg) in tetrahydrofuran (1.5 ml) was desilylated by treatment overnight with tetrabutylammonium fluoride (1.3 ml of a 1 M solution in tetrahydrofuran). The crude product (40 mg) was purified by TLC to give the title compound (27 mg): NMR (CDCl_3) δ 0.76 (s, 18-H's), 0.95, 1.0 (21-H's), 1.3 (25-H's), 1.9 (s, COCH's), 5.1-5.3 (m, NH, 16-H), 6.5 and 6.95 (m, 1-, 2- and 4-H's).

15

20

e) 25-Ethylamino-3-hydroxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I):, $R^1 = R^2 = \text{CH}_3$, $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $X = \text{NH}(\text{CH}_2\text{CH}_3)$, $Y = (\text{CH}_2)_4$, $\Delta 16$ double bond]

25

The title compound is prepared by reduction of the product of (c) above with lithium aluminium hydride in tetrahydrofuran for 3 hours followed by removal of the silyl group according to step (d) above.

30

- 39 -

- f) 25-Methylamino-3-hydroxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = \text{CH}_3$, $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $\text{X} = \text{NH}(\text{CH}_3)$, $\text{Y} = (\text{CH}_2)_4$, $\Delta 16$ double bond] and 25-dimethylamino-3-hydroxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = \text{CH}_3$, $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $\text{X} = \text{N}(\text{CH}_3)_2$, $\text{Y} = (\text{CH}_2)_4$, $\Delta 16$ double bond]

The title compounds are prepared by methylation with methyl iodide/calcium oxide of the product from (c) above and separation of the products by chromatography followed by desilylation as in step (d) above.

- g) 25-(N-Ethyl-N-methylamino)-3-hydroxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = \text{CH}_3$, $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $\text{X} = \text{N}(\text{CH}_3)(\text{CH}_2\text{CH}_3)$, $\text{Y} = (\text{CH}_2)_4$, $\Delta 16$ double bond]

The title compound is prepared by methylation of the N-ethyl 3-silyl ether compound prepared as an intermediate in step (e) above, followed by desilylation according to the procedure in step (d) above.

- h) 25-Acetylamino-3-methoxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = \text{CH}_3$, $R^3 = \alpha\text{-CH}_3$, $R^4 = \text{CH}_3$, $R^5 = \text{H}$, $\text{X} = \text{NH}(\text{COCH}_3)$, $\text{Y} = (\text{CH}_2)_4$, $\Delta 16$ double bond]

The title compound is prepared by methylation of the product of Example 1(d) with sodium hydride/methyl iodide.

i) 25-Acetylamino-3-ethoxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \alpha-CH_3$, $R^4 = CH_3CH_2$, $R^5 = H$, $X = NH(COCH_3)$, $Y = (CH_2)_4$, Δ^{16} double bond]

5

The title compound is prepared as in step (h) above using ethyl iodide in place of methyl iodide.

j) 25-Acetylamino-3-isobutoxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \alpha-CH_3$, $R^4 = (CH_3)_2CHCH_2$, $R^5 = H$, $X = NH(COCH_3)$, $Y = (CH_2)_4$, Δ^{16} double bond]

10

The title compound is prepared as in step (h) above using isobutyl bromide in place of methyl iodide.

15

Alternatively, analogues of any of the compounds in the Examples having $R^4 =$ lower alkyl may be prepared by starting from the corresponding estrone 3-ether and following the remaining steps without modification.

20

k) 25-Benzamido-3-hydroxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \alpha-CH_3$, $R^4 = R^5 = H$, $X = NH(COC_6H_5)$, $Y = (CH_2)_4$, Δ^{16} double bond]

25

The title compound is prepared by substituting benzoyl chloride for acetic anhydride in step (c) above and desilylating the resulting product as in step (d) above.

30

l) 25-Phenylacetylamino-3-hydroxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \alpha-CH_3$, $R^4 = R^5 = H$, $X = NH(CO.CH_2.C_6H_5)$, $Y = (CH_2)_4$, Δ^{16} double bond]

35

The title compound is prepared by substituting phenylacetyl chloride for acetic anhydride in step (c)

above and desilylating the resulting product as in step (d) above.

Example 2

5

a) 3-Triisopropylsilyloxy-23,23a-bishomo-19-nor-chol-1,3,5(10)-triene-24-nitrile [Formula (II): $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $Y = (\text{CH}_2)_4$]

10 The bromide from Preparation 2(c) (130 mg) was treated with α -lithio-acetonitrile as in Example 1 (a) to give the title compound (140 mg crude, 65 mg after chromatography): IR ν_{max} 2250 cm^{-1} ; NMR (CDCl_3) δ 0.80 (s, 18-H's), 6.5 and 6.95 (m, 1-, 2- and 4-H's).

15

b) 25-Amino-3-triisopropylsilyloxy-24-homo-19-nor-cholest-1,3,5(10)-triene [Formula (I): $R^1 = R^2 = \text{CH}_3$, $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $X = \text{NH}_2$, $Y = (\text{CH}_2)_4$]

20 The nitrile from (a) above (65 mg) was treated with methyl cerous chloride as in Example 1 (b) to give the title compound (58 mg): NMR (CDCl_3) δ 0.80 (s, 18-H's), 1.3 (s, 25-H's), 6.5 and 6.95 (m, 1-, 2- and 4-H's).

25

c) 25-Acetylamino-3-triisopropylsilyloxy-24-homo-19-nor-cholest-1,3,5(10)-triene [Formula (I): $R^1 = R^2 = \text{CH}_3$, $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $X = \text{NH}(\text{COCH}_3)$, $Y = (\text{CH}_2)_4$]

30 The amine from (b) above (58 mg) was acetylated as in Example 1(c) to give the title compound (57 mg): NMR (CDCl_3) δ 0.80 (s, 18-H's), 1.3 (s, 25-H's), 1.9 (s, COCH's), 5.1 (s, NH), 6.5 and 6.95 (m, 1-, 2- and 4-H's).

35

d) 25-Acetylamino-3-hydroxy-24-homo-19-nor-cholest-1,3,5(10)-triene [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \alpha-CH_3$, $R^4 = H$, $R^5 = H$, $X = NH(COCH_3)$, $Y = (CH_2)_4$]

5 The silyl ether from (c) above (57 mg) was desilylated as in Example 1 (d) to give the title compound (51 mg crude, 15 mg purified by TLC): NMR ($CDCl_3$) δ 0.80 (s, 18-H's), 1.3 (s, 25-H's), 1.9 (s, $COCH_3$'s), 5.0-5.15 (s, NH), 6.5 and 6.95 (m, 1-, 2- and 4-H's).

10 Example 3

a) 3-Triisopropylsilyloxy-19,26,27-trisnor-cholest-1,3,5(10)-triene-24-one [Formula (V): $R^1 = CH_3$, $R^3 = \alpha-CH_3$, $R^4 = (i-Pr)_3Si$, $R^5 = H$, $Y = (CH_2)_2$]

15 Butyl lithium (0.94 ml, 1.5 mM) was added dropwise to 1-triphenylphosphoranylidene-2-propanone (477 mg) in tetrahydrofuran (12 ml) at -78° and the mixture was
20 stirred for 30 minutes. The bromide from Preparation 3(d) above (260 mg) in tetrahydrofuran (3 ml) was added dropwise at -78° and the reaction mixture was stirred for 30 minutes, allowed to warm to 0° and then stirred for a further 3 hours. After storage overnight at room
25 temperature the solvent was removed and the residue was dissolved in ethanol (15 ml) and water (6 ml) and heated under reflux overnight. The crude product, which had undergone *in situ* desilylation, was purified by
30 chromatography to give the 3-OH analogue of the title compound (160 mg): IR ($CDCl_3$) ν_{max} 1600, 1700, 3160-3460 cm^{-1} ; NMR ($CDCl_3$) δ 0.67 (s, 18-H's), 2.13 (s, 25-H's), 6.3-7.3 (m, 1-, 2- and 4-H's).

35 This product was silylated by treatment with triisopropylsilyl chloride (130 mg) and imadazole (122 mg) in dichloromethane (1 ml) and purified by chromatography to give the title compound: IR ($CDCl_3$) ν_{max}

- 43 -

1600, 1700 cm^{-1} ; NMR (CDCl_3) δ 0.67 (s, 18-H's), 2.07 (s, 25-H's), 6.3-7.2 (m, 1-, 2- and 4-H's).

b) 3-Triisopropylsilyloxy-24-propargyl-19,26,27-
5 trisinor-cholest-1,3,5(10)-trien-24-ol [Formula (I):
 $\text{R}^1 = \text{CH}_3$, $\text{R}^2 = \text{CH}_2\text{C}\equiv\text{CH}$, $\text{R}^3 = \alpha\text{-CH}_3$, $\text{R}^4 = (\text{i-Pr})_3\text{Si}$,
 $\text{R}^5 = \text{H}$, $\text{X} = \text{OH}$, $\text{Y} = (\text{CH}_2)_2$]

A reagent solution was prepared as follows: propargyl
10 bromide (2.53 g, 80% by weight in toluene) in ether
(18 ml) was added dropwise to aluminium powder (900 mg)
and powdered mercuric chloride (45 mg) in ether (4 ml)
and the mixture was refluxed overnight. The total
15 volume of the resulting solution was 24 ml. A portion
of this reagent (0.8 ml) was added dropwise to a
solution of the ketone from (a) above (60 mg) in
tetrahydrofuran (1 ml), and the resulting mixture was
stirred at room temperature for 15 minutes. Ether and
20 wet sodium sulphate were then added to coagulate the
aluminium compounds, whereafter the solution was
filtered and the solvents were removed to give the title
compound (55 mg): IR (CDCl_3) ν_{max} 1600, 3280 cm^{-1} ; NMR
(CDCl_3) δ 0.7 (s, 18-H's), 6.3-7.2 (m, 1-, 2- and 4-H's).

25 c) 3,24-Dihydroxy-24-propargyl-19-26,27-trisinor-
cholest-1,3,5(10)-triene [Formula (I): $\text{R}^1 = \text{CH}_3$, $\text{R}^2 =$
 $\text{CH}_2\text{C}\equiv\text{CH}$, $\text{R}^3 = \alpha\text{-CH}_3$, $\text{R}^4 = \text{R}^5 = \text{H}$, $\text{X} = \text{OH}$, $\text{Y} = (\text{CH}_2)_2$]

The product from (b) above (55 mg) was desilylated as in
30 Example 1(d) to give the title compound (38 mg): IR
(CDCl_3) ν_{max} 1590, 1600, 3300, 3310-3620 cm^{-1} ; NMR (CDCl_3)
 δ 0.7 (s, 18-H's), 1.2 (s, $\text{C}\equiv\text{CH}$), 4.6-5.1 (bs, OH),
6.3-7.2 (m, 1-, 2- and 4-H's).

35

5

10

15

20

25

30

b) 3-Triisopropylsilyloxy-24,24-bispropargyl-19-nor-chol-1,3,5(10),22-tetraen-24-ol [Formula (I): $R^1 = R^2 = CH_2C\equiv CH$, $R^3 = \alpha-CH_3$, $R^4 = (i-Pr)_3Si$, $R^5 = H$, $X = OH$, $Y = CH=CH$]

Propargyl aluminum reagent as prepared as in Example 3(b) (0.7 ml, 5 equivalents) was added dropwise to the ethyl ester from (a) above (55 mg) in tetrahydrofuran (1 ml). The resulting mixture was stirred for 1 hour and then worked up. The product was purified by PTLC to give the title compound (45 mg): IR (CDCl₃) ν_{max} 1600, 3280, 3500-3600 cm⁻¹; NMR (CDCl₃) δ 0.7 (s, 18-H's), 5.4-5.7 (m, side chain -CH=CH's), 6.3-7.3 (m, 1-, 2- and 4-H's).

c) 3,24-Dihydroxy-24,24-bispropargyl-19-nor-chol-1,3,5(10),22-tetraene [Formula (I): $R^1 = R^2 = CH_2C\equiv CH$, $R^3 = \alpha-CH_3$, $R^4 = R^5 = H$, $X = OH$, $Y = CH=CH$]

The silyl ether from (b) above (45 mg) was desilylated by treatment with tetrabutylammonium fluoride (0.3 ml) in tetrahydrofuran (0.3 ml) at room temperature overnight. The product was purified by PTLC to give the title compound (25 mg): IR (CDCl₃) ν_{max} 1580, 1600, 3280, 3520-3620 cm⁻¹; NMR (CDCl₃) δ 0.71 (s, 18-H's), 5.4-5.7 (bm, side chain -CH=CH's), 6.3-7.3 (m, 1-, 2- and 4-H's).

d) 2-Methoxy-3,24-dihydroxy-24,24-bispropargyl-19-nor-chol-1,3,5(10),22-tetraene [Formula (I): $R^1 = R^2 = CH_2C\equiv CH$, $R^3 = \alpha-CH_3$, $R^4 = H$, $R^5 = OCH_3$, $X = OH$, $Y = CH=CH$]

This is prepared from the product of Preparation 6(e) by following the procedures of steps (a)-(c) above.

e) 3,24-Dihydroxy-20-epi-24,24-bispropargyl-19-nor-
chol-1,3,5(10),22-tetraene [Formula (I): $R^1 = R^2 =$
 $CH_2C\equiv CH$, $R^3 = \beta-CH_3$, $R^4 = R^5 = H$, $X = OH$, $Y = CH=CH$]

5 This is prepared from the product of Preparation 8(h) by following the procedures of steps (a)-(c) above.

Example 5

10 a) 3-Hydroxy-25-amino-26,27-bishomo-19-nor-cholest-
1,3,5(10)-trien-23-yne [Formula (I): $R^1 = R^2 = CH_2CH_3$, R^3
 $= \alpha-CH_3$, $R^4 = R^5 = H$, $X = NH_2$, $Y = CH_2-C\equiv C$]

15 Butyl lithium (3.8 ml, 6.1 mmol) was added dropwise to a solution of 1,1-diethylpropargylamine (800 mg) in hexane (20 ml) at 0°. The resulting mixture was stirred for 30 minutes, brought to room temperature, stirred for a further 1.5 hours, and then cooled to 0°. A solution of the 20-bromomethyl compound from Preparation 3(d) (300
20 mg) in hexane (4 ml) was added dropwise, whereafter the solution was stirred for 30 minutes, warmed to 40° and then stirred for 24 hours. The reaction was quenched with ammonium chloride and the product was extracted into ether. The extract was washed, dried and purified
25 by chromatography to give the title compound (110 mg): IR (CDCl₃) ν_{max} 1580, 1600, 3000-3640 cm⁻¹; NMR (CDCl₃) δ 0.7 (s, 18-H's), 6.3-7.3 (m, 1-, 2- and 4-H's).

30 b) 2-Methoxy-3-hydroxy-25-amino-26,27-bishomo-19-nor-
cholest-1,3,5(10)-trien-23-yne [Formula (I): $R^1 = R^2 =$
 CH_2CH_3 , $R^3 = \alpha-CH_3$, $R^4 = H$, $R^5 = OCH_3$, $X = NH_2$, $Y = CH_2C\equiv C$]

This is prepared from the product of Preparation 6(f) by following the procedure of step (a) above.

c) 3-Hydroxy-20-epi-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne [Formula (I): $R^2 = CH_2CH_3$, $R^3 = \beta-CH_3$, $R^4 = R^5 = H$, $X = NH_2$, $Y = CH_2C \equiv C$]

5 This is prepared from the product of Preparation 8(i) by following the procedure of step (a) above.

Example 6

10 a) 3-Hydroxy-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-triene [Formula (I): $R^1 = R^2 = -CH_2CH_3$, $R^3 = \alpha-CH_3$, $R^4 = R^5 = H$, $X = NH_2$, $Y = (CH_2)_3$]

15 A solution of the amine from Example 5(a) (70 mg) in ethanol (3.5 ml) containing 5% platinum on carbon (15 mg) was stirred overnight under hydrogen. The resulting mixture was filtered, the solvent was removed from the filtrate, and the product was purified by PTLC to give the title compound (18 mg): IR (CDCl₃) ν_{max} 1580, 1600, 20 3000-3640 cm⁻¹; NMR (CDCl₃) δ 0.67 (s, 18-H's), 6.3-7.3 (m, 1-, 2- and 4-H's).

b) 2-Methoxy-3-hydroxy-25-amino-26,27-bishomo-19-nor-cholesta-1,3,5(10)-triene [Formula (I): $R^1 = R^2 = CH_2CH_3$, 25 $R^3 = \alpha-CH_3$, $R^4 = H$, $R^5 = OCH_3$, $X = NH_2$, $Y = (CH_2)_3$]

This is prepared from the product of Example 5(b) by following the procedure of step (a) above.

30 c) 3-Hydroxy-20-epi-25-amino-26,26-bishomo-19-nor-cholesta-1,3,5(10)-triene [Formula (I): $R^1 = R^2 = CH_2CH_3$, $R^3 = \beta-CH_3$, $R^4 = R^5 = H$, $X = NH_2$, $Y = (CH_2)_3$]

35 This is prepared from the product of Example 5(c) by following the procedure of step (a) above.

Example 7

5 a) 3-Hydroxy-25-acetylamino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne [Formula (I): $R^1 = R^2 =$
 CH_2CH_3 , $R^3 = \alpha-CH_3$, $R^4 = R^5 = H$, $X = NH(COCH_3)$, $Y =$
 $CH_2-C \equiv C$]

10 The product from Example 5(a) (10mg) was treated at room temperature overnight with acetic anhydride (12 mg) in methanol (0.1 ml) containing proton sponge (12 mg). The reaction mixture was worked up and the product was purified by PTLC to give the title compound (10 mg): NMR ($CDCl_3$) δ 0.67 (s, 18-H's), 1.86 (s, $NHCOCH_3$'s), 6.3-7.3 (m, 1-, 2- and 4-H's).

15 b) 2-Methoxy-3-hydroxy-25-acetylamino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne [Formula (I): $R^1 =$
 $R^2 = CH_2CH_3$, $R^3 = \alpha-CH_3$, $R^4 = H$, $R^5 = OCH_3$, $X = NH(COCH_3)$, $Y =$
 $CH_2-C \equiv C$]

20 This is prepared from the product of Example 5(b) by following the procedure of step (a) above.

25 c) 3-Hydroxy-20-epi-25-acetylamino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne [Formula (I): $R^1 = R^2 =$
 CH_2CH_3 , $R^3 = \alpha-CH_3$, $R^4 = R^5 = H$, $X = NH(COCH_3)$, $Y =$
 $CH_2-C \equiv C$]

30 This is prepared from the product of Example 5(c) following the procedure of step (a) above.

Example 8

a) 3-Triisopropylsilyloxy-22-hydroxy-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne [Formula (I): $R^1 = R^2 = CH_2CH_3$, $R^3 = \alpha-CH_3$, $R^4 = (i-Pr)_3Si$, $R^5 = H$, $X = NH_2$, $Y = CH(OH)-C\equiv C$]

The 20-formyl compound from Preparation 4 (200 mg) in tetrahydrofuran (1 ml) was added at -78° to a solution of the anion prepared from 1,1-diethylpropargylamine (400 mg) and butyl lithium (1.9 ml, 3 mmol) as in Example 5(a). The resulting mixture was stirred at -78° for 30 minutes, quenched with ammonium acetate, brought to room temperature and worked up. The product was purified by chromatography to give the title compound (150 mg): NMR ($CDCl_3$) δ 0.7 (s, 18-H's), 4.3-4.6 (bs, 22-HOCH), 6.3-7.3 (m, 1-, 2- and 4-H's).

b) 3,22-Dihydroxy-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne [Formula (I), $R^1 = R^2 = CH_2CH_3$, $R^3 = \alpha-CH_3$, $R^4 = R^5 = H$, $X = NH_2$, $Y = CH(OH)-C\equiv C$]

The silyl compound from (a) above (50 mg) was desilylated by treatment with tetrabutylammonium fluoride (0.3 ml) in tetrahydrofuran (0.3 ml) overnight at room temperature. The resulting mixture was worked up and the product was purified by PTLC to give the title compound: NMR ($CDCl_3$) δ 0.7 (s, 18-H's), 4.3-4.6 (bs, 22-HOCH), 6.3-7.3 (m, 1-, 2- and 4-H's).

c) 2-Methoxy-3,22-dihydroxy-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne [Formula (I): $R^1 = R^2 = CH_2CH_3$, $R^3 = \alpha-CH_3$, $R^4 = H$, $R^5 = OCH_3$, $X = NH_2$, $Y = CH(OH)-C\equiv C$]

This is prepared from the product of Preparation 6(e) following the procedures of steps (a) and (b) above.

d) 3,22-Dihydroxy-20-epi-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne [Formula (I): $R^1 = R^2 = CH_2CH_3$, $R^3 = \beta-CH_3$, $R^4 = R^5 = H$, $X = NH_2$, $Y = CH(OH)-C\equiv C$]

5 This is prepared from the product of Preparation 8(h) following the procedures of steps (a) and (b) above.

Example 9

10 a) 2-Methoxy-3-triisopropylsilyloxy-23,23a-bishomo-19-nor-chol-1,3,5(10),16-tetraene-24-nitrile [Formula (II): $R^3 = \alpha-CH_3$, $R^4 = (i-Pr)_3Si$, $R^5 = OCH_3$, $Y = (CH_2)_4$, Δ^{16} double bond]

15 A solution of α -lithio acetonitrile was prepared as follows: acetonitrile (0.32 ml) in tetrahydrofuran (2 ml) was added dropwise at -78° to a solution of butyl lithium (3.75 ml of a 1.6 M solution in hexane) in tetrahydrofuran (4 ml) and the solution stirred for 50
20 minutes. All but a sixth of the solution (ca 1 mmol) was discarded, whereafter the bromide from Preparation 6(d) (200 mg) in tetrahydrofuran (2 ml) was added dropwise while maintaining the temperature at -78° . The resulting mixture was stirred for 1 hour, allowed to
25 warm to -30° , stirred for a further hour, cooled back to -78° , quenched with ammonium chloride, and worked up. The product was purified by chromatography to give the title compound (145 mg): IR ($CDCl_3$) ν_{max} 1600, 2240 cm^{-1} ; NMR ($CDCl_3$) δ 0.8 (s, 18-H's), 3.7 (s, OCH's), 5.0-5.3
30 (bs, 16-H's), 6.34, 6.6 (s, 1,4-H's).

b) 2-Methoxy-3-triisopropylsilyloxy-24-homo-25-amino-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \alpha-CH_3$, $R^4 = (i-Pr)_3Si$, $R^5 = OCH_3$, $X = NH_2$, $Y = (CH_2)_4$, Δ^{16} double bond]

35

Cerium chloride (384 mg, 1.56 mmol, previously dried at

- 51 -

<0.5 mm and 140° for 3 hours) was suspended in tetrahydrofuran (4 ml). This mixture was stirred overnight and then cooled to -78°, whereafter methyl lithium (1.9 mmol, 1.34 ml of a 1.4 M solution in ether) was added dropwise and the mixture was stirred for 15 minutes at -78°, warmed to 0°, stirred for 15 minutes and cooled back to -78°. The nitrile from (a) above (145 mg) in tetrahydrofuran (2 ml) was then added dropwise, and the mixture was stirred for 1.5 hours and then quenched with aqueous ammonium hydroxide.

Following work up, removal of the solvent gave the title compound (145 mg): IR (CDCl₃) ν_{\max} 1600, 3100-3700 cm⁻¹; NMR (CDCl₃) δ 0.77 (s, 18-H's), 1.3 (s, 26,27-H's), 3.67 (s, OCH's), 5.0-5.3 (bs, 16-H's), 6.4, 6.58 (s, 1,4-H's).

c) 2-Methoxy-3-triisopropylsilyloxy-24-homo-25-acetyl-amino-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I):
R¹ = R² = CH₃, R³ = α -CH₃, R⁴ = (i-Pr)₃Si, R⁵ = OCH₃, X =
NH(COCH₃), Y = (CH₂)₄, Δ 16 double bond]

Acetylation of the amine from (b) above (85 mg) with acetic anhydride (0.425 ml) and pyridine (0.425 ml) in dichloromethane (2 ml) overnight at room temperature gave the title compound (65 mg, purified by PTLC): IR (CDCl₃) ν_{\max} 1600, 1710, 3420 cm⁻¹; NMR (CDCl₃) δ 0.77 (s, 18-H's), 1.88 (s, COCH₃), 3.7 (s, OCH's), 4.7-5.3 (b, NH', 16-H's), 6.43, 6.6 (s, 1,4-H's).

d) 2-Methoxy-3-hydroxy-24-homo-25-acetylamino-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): R¹ = R² =
CH₃, R³ = α -CH₃, R⁴ = H, R⁵ = OCH₃, X = NH(COCH₃), Y =
(CH₂)₄, Δ 16 double bond]

The amide from (c) above (65 mg) was desilylated by treatment with tetrabutylammonium fluoride (0.3 ml) in tetrahydrofuran (0.3 ml) for 4 hours, and the crude

- 52 -

product was isolated by PTLC to give the title compound (45 mg): IR (CDCl₃) ν_{\max} 1590, 1710, 3420, 3520 cm⁻¹; NMR (CDCl₃) δ 0.8 (s, 18-H's), 1.3 (s, 26,27-H's), 1.86 (s, COCH₃), 3.78 (s, OCH's), 4.9-5.3 (b, NH, 16H's), 5.3-5.6 (s, OH), 6.47, 6.63 (s, 1,4-H's).

e) 2-Methoxy-3-hydroxy-24-homo-25-amino-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): R¹ = R² = CH₃, R³ = α -CH₃, R⁴ = H, R⁵ = OCH₃, X = NH₂, Y = (CH₂)₄, Δ 16 double bond]

The title compound is obtained by desilylation of the product from (b) above according to the procedure of step (d) above.

f) 2-Methoxy-3-hydroxy-25-acetylamino-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): R¹ = R² = CH₃, R³ = α -CH₃, R⁴ = H, R⁵ = OCH₃, X = NH(COCH₃), Y = (CH₂)₃, Δ 16 double bond]

This is prepared by substituting sodium cyanide for the anion in step (a) above and thereafter following the procedures of steps (b)-(d) above.

g) 2-Methoxy-3-hydroxy-25-amino-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): R¹ = R² = CH₃, R³ = α -CH₃, R⁴ = H, R⁵ = OCH₃, X = NH₂, Y = (CH₂)₂, Δ 16 double bond]

This is prepared by substituting sodium cyanide for the anion in step (a) above and thereafter following the procedures of steps (b) and (d) above.

Example 10

- 5 a) Triisopropylsilyloxy-23,23a-bishomo-19-nor-
chol-1,3,5(10),6,8,16-hexaene-24-nitrile [Formula (II):
R³ = α -CH₃, R⁴ = (i-Pr)₃Si, R⁵ = H, Y = (CH₂)₄, Δ 6, Δ 8 and
 Δ 16 double bonds]

Reaction of the bromide from Preparation 7(e) according
to the method of Example 9(a) gave the title compound:
10 IR (CDCl₃) ν_{\max} 1590, 1610, 2230 cm⁻¹; NMR (CDCl₃) δ 0.66
(s, 18-H's), 5.2-5.5 (bs, 16-H's), 6.8-8.0 (m, 1-, 2-,
4-, 6- and 7-H's).

- 15 b) 3-Triisopropylsilyloxy-24-homo-25-amino-19-nor-
cholest-1,3,5(10),6,8,16-hexaene [Formula (I): R¹ = R² =
CH₃, R³ = α -CH₃, R⁴ = (i-Pr)₃Si, R⁵ = H, X = NH₂, Y =
(CH₂)₄, Δ 6, Δ 8 and Δ 16 double bonds]

The title compound was prepared by reaction of the
20 nitrile from (a) above as in Example 9(b).

- c) 3-Triisopropylsilyloxy-24-homo-25-acetylamino-19-
nor-cholest-1,3,5(10),6,8,16-hexaene [Formula (I): R¹ =
R² = CH₃, R³ = α -CH₃, R⁴ = (i-Pr)₃Si, R⁵ = H, X =
25 NH(COCH₃), Y = (CH₂)₄, Δ 6, Δ 8 and Δ 16 double bonds]

Acetylation of the amine from (b) above as in Example
9(c) gave the title compound (45 mg): IR (CDCl₃) ν_{\max}
1595, 1605, 1670, 3420 cm⁻¹; NMR (CDCl₃) δ 0.67 (s, 18-
30 H's), 1.3 (s, 26,27-H's), 1.87 (s, COCH₃), 4.7-5.1 (b,
NH), 5.1-5.4 (b, 16-H) 6.7-8.0 (s, 1-, 2-, 4-, 6- and 7-
H's).

d) 3-Hydroxy-24-homo-25-acetylamino-19-nor-cholest-1,3,5(10),6,8,16-hexaene [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \alpha-CH_3$, $R^4 = R^5 = H$, $X = NH(COCH_3)$, $Y = (CH_2)_4$, $\Delta 6$, $\Delta 8$ and $\Delta 16$ double bonds]

5

The amide from (c) above (45 mg) was desilylated by treatment with tetrabutylammonium fluoride (0.25 ml) in tetrahydrofuran (0.25 ml) at room temperature overnight to give the title compound (28 mg, isolated by PTLC): IR (CDCl₃) ν_{max} 1590, 1610, 1650, 3440 cm⁻¹; NMR (CDCl₃) δ 0.67 (s, 18-H's), 1.0 (d, 21-H's), 1.27 (s, 26,27-H's), 1.88 (s, COCH₃), 4.8-5.4 (b, NH, 16-H), 6.7-8.0 (m, 1-, 2-, 4-, 6- and 7-H's).

10

15

e) 3-Hydroxy-24-homo-25-amino-19-nor-cholest-1,3,5(10),6,8,16-hexaene [Formula (I) $R^1 = R^2 = CH_3$, $R^3 = \alpha-CH_3$, $R^4 = R^5 = H$, $X = NH_2$, $Y = (CH_2)_4$, $\Delta 6$, $\Delta 8$ and $\Delta 16$ double bonds]

20

The title compound is obtained by desilylation of the product from (b) above according to the procedure of (d) above.

Example 11

25

a) 3-Triisopropylsilyloxy-25-triethylsilyloxy-19-nor-cholest-1,3,5(10)-trien-23-yne [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \alpha-CH_3$, $R^4 = (i-Pr)_3Si$, $R^5 = H$, $X = OSi(CH_2CH_3)_3$, $Y = CH_2C \equiv C$]

30

Butyl lithium (2.5 ml, 4 mmol) was added dropwise to a solution of [(1,1-dimethyl-2-propynyl)oxy]triethylsilane (792 mg) in hexane containing hexamethylphosphoramide (0.8 ml) at 0°. The resulting mixture was stirred for 30 minutes at that temperature and for a further 1.5 hours at room temperature, and was then cooled again to 0°, whereafter a solution of the bromide from

35

- 55 -

Preparation 3(d) (210 mg) in hexane (4 ml) was added dropwise. The mixture was stirred for 30 minutes at 0°, 2 hours at room temperature, and overnight at 45°C. The reaction was quenched with ammonium chloride and worked up. Chromatography gave a mixture of the 25-desilylated analogue (15 mg, see below) and the title compound (210 mg): NMR (CDCl₃) δ 0.72 (s, 18-H's), 1.48 (s, 26,27-H's, some at 1.42 for the silylated compound), 6.3-7.3 (1-, 2- and 4-H's).

b) 3,25-Dihydroxy-19-nor-cholest-1,3,5(10)-trien-23-yne [Formula (I), R¹ = R² = CH₃, R³ = α-CH₃, R⁴ = R⁵ = H, X = OH, Y = CH₂C≡C]

The product from (a) above was desilylated as in Example 1(d) and purified by PTLC to give the title compound (50 mg, insoluble and difficult to manipulate): IR (CDCl₃) ν_{max} 1600, 3480 cm⁻¹.

c) 3,25-Dihydroxy-19-nor-cholest-1,3,5(10)-triene [Formula (I), R¹ = R² = CH₃, R³ = α-CH₃, R⁴ = R⁵ = H, X = OH, Y = (CH₂)₃]

A solution of the product from (b) above (40 mg) in ethyl acetate (16 ml) containing palladium (5% on carbon, 10 mg) was stirred overnight under hydrogen. The reaction mixture was worked up and the product was purified by PTLC to give the title compound (28 mg): NMR (CDCl₃) δ 0.7 (s, 18-H's), 1.18 (s, 26,27-H's), 6.2, 7.3 (m, 1-, 2- and 4-H's).

d) 2-Methoxy-3,25-dihydroxy-19-nor-cholest-1,3,5(10)-trien-23-yne [Formula (I): R¹ = R² = CH₃, R³ = α-CH₃, R⁴ = H, R⁵ = OCH₃, X = OH, Y = CH₂C≡C]

This is prepared from the product of Preparation 6(f) by following the procedures of the above steps (a) and (b).

e) 3,25-Dihydroxy-20-epi-19-nor-cholest-1,3,5(10)-trien-23-yne [Formula (I): $R^1 = R^2 = \text{CH}_3$, $R^3 = \beta\text{-CH}_3$, $R^4 = R^5 = \text{H}$, $X = \text{OH}$, $Y = \text{CH}_2\text{C}\equiv\text{C}$]

5 This is prepared from the product of Preparation 8(i) by following the procedures of the above steps (a) and (b).

f) 2-Methoxy-3,25-dihydroxy-19-nor-cholest-1,3,5(10)-triene [Formula (I): $R^1 = R^2 = \text{CH}_3$, $R^3 = \alpha\text{-CH}_3$, $R^4 = \text{H}$, $R^5 = \text{OCH}_3$, $X = \text{OH}$, $Y = (\text{CH}_2)_3$]

10

This is prepared by hydrogenation of the product from (d) above as in step (c) above.

g) 3,25-Dihydroxy-20-epi-19-nor-cholest-1,3,5(10)-triene [Formula (I): $R^1 = R^2 = \text{CH}_3$, $R^3 = \beta\text{-CH}_3$, $R^4 = R^5 = \text{H}$, $X = \text{OH}$, $Y = (\text{CH}_2)_3$]

15

This is prepared by hydrogenation of the product from (e) above as in step (c) above.

20

Example 12

a) 3-Triisopropylsilyloxy-24,24a-bishomo-19-nor-chole-1,3,5(10),22,24(24a)pentaene-24b-carboxylic acid ethyl ester [Formula (VI): $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $R^6 = \text{CH}_2\text{CH}_3$, $Y = \text{CH}=\text{CH}-\text{CH}=\text{CH}$]

25

The aldehyde from Preparation 4(b) (150 mg) was stirred at 105° for 4 hours in dimethylsulphoxide (3 ml) containing the ylid prepared by washing a solution of ethyl-4-bromotrimethylphosphonium butenoate (364 mg) in dichloromethane with 2N sodium hydroxide and removing the solvents. The reaction mixture was worked up and the product was purified to give the 3-OH analogue of the title compound (40 mg) and the title compound (100 mg): IR (CDCl_3) ν_{max} 1600, 1630, 1690 cm^{-1} ; NMR (CDCl_3) δ

30

35

0.73 (s, 18-H's), 3.8-4.4 (q, -O-CH of ethyl), 5.3-5.8, 6.3-7.7 (m, side chain -CH=CH's, 1-, 2- and 4-H's).

5 **b) 3-Triisopropylsilyloxy-25-hydroxy-24,24a-bishomo-19-nor-cholest-1,3,5(10),22,24(24a)-pentaene [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \alpha-CH_3$, $R^4 = (i-Pr)_3Si-$, $R^5 = H$, $X = OH$, $Y = CH=CH-CH=CH$]**

10 Methyl lithium (0.36 ml, 5 equivalents) was added dropwise to a solution of the ester from (a) above (58 mg) in tetrahydrofuran (4 ml) at -45° , and the resulting mixture was stirred for 30 minutes, then quenched and worked up. The product was purified by P_TL_C to give the title compound (27 mg): IR (CDCl₃) ν_{max} 1596, 3650 cm⁻¹;
15 NMR (CDCl₃) δ 0.7 (s, 18-H's), 1.32 (s, 26,27-H's), 5.2-6.2 (22-, 23-, 24- and 24a-H's), 6.2-7.4 (m, 1-, 2- and 4-H's).

20 **c) 3,25-Dihydroxy-24,24a-bishomo-19-nor-cholest-1,3,5(10),22,24(24a)-pentaene [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \alpha-CH_3$, $R^4 = R^5 = H$, $X = OH$, $Y = CH=CH-CH=CH$]**

25 The silyl ether from (b) above (27 mg) was desilylated as in Example 1(d) and purified by PTL_C to give title compound (18 mg): NMR (CDCl₃/CD₃OH) δ 0.72 (s, 18-H's), 1.3 (s, 26,27-H's), 5.1-6.3 (22-, 23-, 24- and 24a-H's), 6.3-7.4 (m, 1-, 2- and 4-H's).

30 Example 13

35 **a) 3-Triisopropylsilyloxy-20-epi-23,23a-bishomo-19-nor-chol-1,3,5(10),16-tetraene-24-nitrile [Formula (II): $R^3 = \beta-CH_3$, $R^4 = (i-Pr)_3Si$, $R^5 = H$, $Y = (CH_2)_4$, Δ^{16} double bond]**

Treatment of the bromide from Preparation 8(g) (350 mg) with the lithium salt of acetonitrile according to the

procedure of Example 3(a) gave the title compound: IR ν_{\max} 2250, 1610, 1450-1600 (3 bands) cm^{-1} ; NMR (CDCl_3) δ 0.78 (s, 18-H's), 5.2 (bs, 16-H), 6.5, 6.95 (m, 1-, 2- and 4-H's).

5

b) 25-Amino-3-triisopropylsilyloxy-20-epi-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = \text{CH}_3$, $R^3 = \beta\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si-}$, $R^5 = \text{H}$, $\text{X} = \text{NH}_2$, $\text{Y} = \text{-(CH}_2\text{)}_4$, Δ^{16} double bond]

10

The nitrile from (a) above was treated with cerium chloride/methyl lithium according to the procedure of Example 3(b) to give the title compound (100mg): IR (CDCl_3) ν_{\max} 1610, 1450-1600 (3 bands) cm^{-1} ; NMR (CDCl_3) δ 0.78 (s, 18-H's), 1.2 (26,27-H's), 5.2 (bs, 16-H), 6.5, 6.95 (m, 1-, 2- and 4-H's).

15

c) 25-Amino-3-hydroxy-20-epi-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = \text{CH}_3$, $R^3 = \beta\text{-CH}_3$, $R^4 = R^5 = \text{H}$, $\text{X} = \text{NH}_2$, $\text{Y} = (\text{CH}_2)_4$, Δ^{16} double bond]

20

The silyl ether from (b) above (40 mg) was desilylated as in Example 1(d) to give the title compound: IR (CDCl_3) ν_{\max} 3600, 1615, 1450-1600 (2 bands) cm^{-1} ; NMR (CDCl_3) δ 0.78 (s, 18-H's), 1.05 (d, 21-H's), 1.2 (26,27-H's), 3.9 (bs, 3H [exchanges with D_2O] - OH, NH's), 5.2 (bs, 16-H), 6.5, 6.95 (m, 1-, 2- and 4-H's).

25

d) 25-Acetylmino-3-triisopropylsilyloxy-20-epi-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = \text{CH}_3$, $R^3 = \beta\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si-}$, $R^5 = \text{H}$, $\text{X} = \text{NH}(\text{COCH}_3)$, $\text{Y} = (\text{CH}_2)_4$, Δ^{16} double bond]

30

The silyl ether from (b) above (60 mg) was acetylated as in Example 3(c) to give the title compound: IR (CDCl_3) ν_{\max} 3420, 1660, 1610, 1450-1600 (2 bands) cm^{-1} ; NMR (CDCl_3) δ 0.78 (s, 18-H's), 1.2 (26,27-H's), 1.9 (bs,

35

- 59 -

NH), 5.2 (bs, 16-H), 6.5, 6.95 (m, 1-, 2- and 4-H's).

5 e) 25-Acetylamino-3-hydroxy-20-epi-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \beta-CH_3$, $R^4 = R^5 = H$, $X = NH(COCH_3)$, $Y = -(CH_2)_4-$, $\Delta 16$ double bond]

10 The silyl ether from (d) above (60 mg) was desilylated as in Example 1(d) to give the title compound (36 mg):
IR ν_{max} 3420, 1610, 1665, 1450-1600 (2 bands) cm^{-1} ; NMR ($CDCl_3$) δ 0.78 (s, 18-H's), 1.2 (26,27-H's), 1.9 (bs, NH), 5.2 (bs, 16-H), 6.5, 6.95 (m, 1-, 2- and 4-H's).

15 f) 25-Amino-3-hydroxy-20-epi-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \beta-CH_3$, $R^4 = R^5 = H$, $X = NH_2$, $Y = (CH_2)_3$, $\Delta 16$ double bond]

20 This is prepared by substituting sodium cyanide for the anion in step (a) above and thereafter following the procedures of steps (b) and (c) above.

25 g) 25-Acetylamino-3-hydroxy-20-epi-24-homo-19-nor-cholest-1,3,5(10),16-tetraene [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \beta-CH_3$, $R^4 = R^5 = H$, $X = NH_2$, $Y = (CH_2)_3$, $\Delta 16$ double bond]

This is prepared by substituting sodium cyanide for the anion in step (a) above and thereafter following the procedures of steps (a), (b) and (d) above.

30

Example 14

5 a) 3-Triisopropylsilyloxy-23,23a-bishomo-19-nor-chol-
1,3,5(10),6,16-pentaen-24-nitrile [Formula (II): $R^3 =$
 $\alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $\text{Y} = (\text{CH}_2)_4$, $\Delta 6$ and $\Delta 16$
double bonds]

10 Reaction of the bromide from Preparation 9(e) in
accordance with the procedure of Example 9(a) gave the
title compound: IR (CDCl_3) ν_{max} 1590, 1615, 2240 cm^{-1} ; NMR
(CDCl_3) δ 0.67 (s, 18-H's), 5.2-5.5 (b, 16-H's), 6.7-8.0
(m, 1-, 2- and 4-H's).

15 b) 3-Triisopropylsilyloxy-24-homo-25-amino-19-nor-
cholest-1,3,5(10),6,16-pentaene [Formula (I): $R^1 = R^2 =$
 CH_3 , $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $\text{X} = \text{NH}_2$, $\text{Y} =$
 $(\text{CH}_2)_4$, $\Delta 6$ and $\Delta 16$ double bonds]

20 The title compound was prepared from the nitrile from
(a) above as in Example 9(b).

25 c) 3-Triisopropylsilyloxy-24-homo-25-acetylamino-19-
nor-cholest-1,3,5(10),6,16-pentaene [Formula (I): $R^1 = R^2$
 $= \text{CH}_3$, $R^3 = \alpha\text{-CH}_3$, $R^4 = (\text{i-Pr})_3\text{Si}$, $R^5 = \text{H}$, $\text{X} = \text{NH}(\text{COCH}_3)$, Y
 $= (\text{CH}_2)_4$, $\Delta 6$ and $\Delta 16$ double bonds]

30 Acetylation of the amine from (b) above as in Example
9(c) gave the title compound (60 mg): IR (CDCl_3) ν_{max}
1590, 1615, 1660, 3420 cm^{-1} ; NMR (CDCl_3) δ 0.67 (s, 18-
H's), 1.26 (s, 26,27-H's), 1.87 (s, COCH_3), 4.9-5.2 (b,
NH), 5.2-5.5 (b, 16-H), 6.7-9.0 (s, 1-, 2-, 4- and 6-
H's).

d) 3-Hydroxy-24-homo-25-acetylamino-19-nor-cholest-1,3,5(10),6,16-pentaene [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \alpha-CH_3$, $R^4 = H$, $R^5 = H$, $X = NH(COCH_3)$, $Y = (CH_2)_4$, $\Delta 6$ and $\Delta 16$ double bonds]

5

The amide from (c) above (50 mg) was desilylated by treatment with tetrabutylammonium fluoride (0.3 ml) in tetrahydrofuran (0.35 ml) at room temperature for 4 hours to give the title compound (36 mg, isolated by

10 PTLC): IR ($CDCl_3$) ν_{max} 1590, 1610, 1650, 3440-3640 cm^{-1} ; NMR ($CDCl_3$) δ 0.63 (s, 18-H's), 1.3 (s, 26,27-H's), 5.0-5.5 (b, NH, 16-H), 6.7-8.0 (m, 1,2-H's).

e) 3-Hydroxy-24-homo-25-amino-19-nor-cholest-1,3,5(10),6,16-pentaene [Formula (I): $R^1 = R^2 = CH_3$, $R^3 = \alpha-CH_3$, $R^4 = H$, $R^5 = H$, $X = NH_2$, $Y = (CH_2)_4$, $\Delta 6$ and $\Delta 16$ double bonds]


15

The title compound is obtained by desilylation of the product from step (b) above by the procedure of step (d) above.

20

Claims:

1. Compounds of formula (I)



in which:

R^1 and R^2 , which may be the same or different, each represents a lower alkyl, alkenyl or alkynyl group;

R^3 represents a methyl group having α - or β -configuration;

R^4 represents a hydrogen atom or an etherifying or esterifying group;

R^5 represents a hydrogen atom, a hydroxyl group or a lower alkoxy group;

X represents a group OR^4 , wherein R^4 is as defined above, or a group NR^6R^7 wherein R^6 represents a hydrogen atom, an aliphatic or araliphatic organic group, or an acyl group comprising an aliphatic, araliphatic or aryl organic group linked to the nitrogen atom by way of a carbonyl group; and R^7 is a hydrogen atom or a lower alkyl group;

Y represents a lower alkylene, alkenylene or alkynylene group optionally substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group; and

the dotted lines signify that double bonds may be present at the 16(17)-position and/or either at the 6(7)- and 8(9)-positions or at the 7(8)-position.

2. Compounds of formula (I) as claimed in claim 1

wherein R¹ and R² are independently selected from C₁₋₆ alkyl groups and C₂₋₇ alkenyl and alkynyl groups.

3. Compounds of formula (I) as claimed in claim 2
5 wherein R¹ and R² are straight chain groups.

4. Compounds of formula (I) as claimed in claim 2
wherein R¹ and R² are selected from methyl, ethyl and
propargyl groups.

10 5. Compounds of formula (I) as claimed in any of the
preceding claims wherein R⁴ a hydrogen atom, a silyl
group, a C₁₋₆ alkyl group optionally interrupted by one
or more oxygen atoms or substituted by a lower
15 cycloalkyl group, a cyclic ether group, a C₁₋₆ alkanoyl
group, an aroyl group, a C₁₋₆ alkane sulphonyl or
halogenated methane sulphonyl group, or an arene
sulphonyl group.

20 6. Compounds of formula (I) as claimed in claim 5
wherein R⁴ is a hydrogen atom.

7. Compounds of formula (I) as claimed in claim 5
wherein R⁴ is a metabolically labile group or a lower
25 alkyl group.

8. Compounds of formula (I) as claimed in any of the
preceding claims wherein R⁵ represents a hydrogen atom or
a methoxy group.

30 9. Compounds of formula (I) as claimed in any of the
preceding claims wherein X represents a hydroxyl group
or a group of formula NR⁶R⁷ wherein:

35 R⁶ is a C₁₋₆ alkyl group, C₆₋₁₂ carbocyclic aryl C₁₋₄
alkyl group, C₁₋₆ alkanoyl group, C₆₋₁₂ carbocyclic aryl
C₂₋₅ alkanoyl group, C₇₋₁₃ carbocyclic aroyl group or any
of the preceding groups substituted by one or more halo,

16. The compounds:

- 25-acetylamino-3-hydroxy-24-homo-19-nor-cholest-
1,3,5(10),16-tetraene;
- 5 25-ethylamino-3-hydroxy-24-homo-19-nor-cholest-
1,3,5(10),16-tetraene;
- 25-methylamino-3-hydroxy-24-homo-19-nor-cholest-
1,3,5(10),16-tetraene;
- 25-dimethylamino-3-hydroxy-24-homo-19-nor-cholest-
10 1,3,5(10),16-tetraene;
- 25-(N-ethyl-N-methylamino)-3-hydroxy-24-homo-19-
nor-cholest-1,3,5(10),16-tetraene;
- 25-acetylamino-3-methoxy-24-homo-19-nor-cholest-
1,3,5(10),16-tetraene;
- 15 25-acetylamino-3-ethoxy-24-homo-19-nor-cholest-
1,3,5(10),16-tetraene;
- 25-acetylamino-3-isobutoxy-24-homo-19-nor-cholest-
1,3,5(10),16-tetraene;
- 25-benzamido-3-hydroxy-24-homo-19-nor-cholest-
20 1,3,5(10),16-tetraene;
- 25-phenylacetylamino-3-hydroxy-24-homo-19-nor-
cholest-1,3,5(10),16-tetraene;
- 25-acetylamino-3-hydroxy-24-homo-19-nor-cholest-
1,3,5(10)-triene;
- 25 3,24-dihydroxy-24-propargyl-19-26,27-trisnor-
cholest-1,3,5(10)-triene;
- 2-methoxy-3,24-dihydroxy-24-propargyl-19,26,27-
trisnor-cholesta-1,3,5(10)-triene;
- 3,24-dihydroxy-20-epi-24-propargyl-19,26,27-
30 trisnor-cholest-1,3,5(10)-triene;
- 3,24-dihydroxy-24,24-bispropargyl-19-nor-cholest-
1,3,5(10),22-tetraene;
- 2-methoxy-3,24-dihydroxy-24,24-bispropargyl-19-nor-
chol-1,3,5(10),22-tetraene;
- 35 3,24-dihydroxy-20-epi-24,24-bispropargyl-19-nor-
chol-1,3,5(10),22-tetraene;
- 3-hydroxy-25-amino-26,27-bishomo-19-nor-cholest-

1,3,5(10)-trien-23-yne;

2-methoxy-3-hydroxy-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

5 3-hydroxy-20-epi-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

3-hydroxy-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-triene;

2-methoxy-3-hydroxy-25-amino-26,27-bishomo-19-nor-cholesta-1,3,5(10)-triene;

10 3-hydroxy-20-epi-25-amino-26,26-bishomo-19-nor-cholesta-1,3,5(10)-triene;

3-hydroxy-25-acetylamino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

15 2-methoxy-3-hydroxy-25-acetylamino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

3-hydroxy-20-epi-25-acetylamino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

3,22-dihydroxy-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

20 2-methoxy-3,22-dihydroxy-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

3,22-dihydroxy-20-epi-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

25 2-methoxy-3-hydroxy-24-homo-25-acetylamino-19-nor-cholest-1,3,5(10),16-tetraene;

2-methoxy-3-hydroxy-24-homo-25-amino-19-nor-cholest-1,3,5(10),16-tetraene;

2-methoxy-3-hydroxy-25-acetylamino-19-nor-cholest-1,3,5(10),16-tetraene;

30 2-methoxy-3-hydroxy-25-amino-19-nor-cholest-1,3,5(10),16-tetraene;

3-hydroxy-24-homo-25-acetylamino-19-nor-cholest-1,3,5(10),6,8,16-hexaene;

35 3-hydroxy-24-homo-25-amino-19-nor-cholest-1,3,5(10),6,8,16-hexaene;

3,25-dihydroxy-19-nor-cholest-1,3,5(10)-trien-23-yne;

- 3,25-dihydroxy-19-nor-cholest-1,3,5(10)-triene;
2-methoxy-3,25-dihydroxy-19-nor-cholest-1,3,5(10)-
trien-23-yne;
3,25-dihydroxy-20-epi-19-nor-cholest-1,3,5(10)-
5 trien-23-yne;
2-methoxy-3,25-dihydroxy-19-nor-cholest-1,3,5(10)-
triene;
3,25-dihydroxy-20-epi-19-nor-cholest-1,3,5(10)-
triene;
10 3,25-dihydroxy-24,24a-bishomo-19-nor-cholest-
1,3,5(10),22,24(24a)-pentaene;
25-amino-3-hydroxy-20-epi-24-homo-19-nor-cholest-
1,3,5(10),16-tetraene;
25-acetylamino-3-hydroxy-20-epi-24-homo-19-nor-
15 cholest-1,3,5(10),16-tetraene;
25-amino-3-hydroxy-20-epi-19-nor-cholest-
1,3,5(10),16-tetraene;
25-acetylamino-3-hydroxy-20-epi-24-homo-19-nor-
cholest-1,3,5(10),16-tetraene;
20 3-hydroxy-24-homo-25-acetylamino-19-nor-cholest-
1,3,5(10),6,16-pentaene; and
3-hydroxy-24-homo-25-amino-19-nor-cholest-
1,3,5(10),6,16-pentaene.
- 25 17. Active compounds of formula (I) as claimed in any
preceeding claim for use in management of neoplastic
disease; as agents to promote wound healing; in burn
management; in treatment of bone diseases, autoimmune
disease, host-graft reaction, transplant rejection,
30 inflammatory diseases, neoplasias or hyperplasias,
myopathy, enteropathy or spondylitic heart disease; in
suppression of parathyroid hormone; in treatment of
dermatological diseases, hypertension, rheumatoid
arthritis, psoriatic arthritis, secondary
35 hyperparathyroidism, asthma, cognitive impairment or
senile dementia; in fertility control in either human or
animal subjects; in management of disorders involving

blood clotting; or in reduction of serum cholesterol.

18. The use of an active compound of formula (I) as claimed in any one of claims 1 to 16 for the manufacture of a medicament for use in management of neoplastic disease; as an agent to promote wound healing; in burn management; in treatment of bone diseases, autoimmune disease, host-graft reaction, transplant rejection, inflammatory diseases, neoplasias or hyperplasias, myopathy, enteropathy or spondylitic heart disease; in suppression of parathyroid hormone; in treatment of dermatological diseases, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism, asthma, cognitive impairment or senile dementia; in fertility control in either human or animal subjects; in management of disorders involving blood clotting; or in reduction of serum cholesterol.

19. Pharmaceutical compositions comprising an active compound of formula (I) as claimed in any one of claims 1 to 16 in admixture with one or more physiologically acceptable carriers or excipients.

20. A method of treatment of a human or animal subject in the management of neoplastic disease; to promote wound healing; in burn management; in treatment of bone diseases, autoimmune disease, host-graft reaction, transplant rejection, inflammatory diseases, neoplasias or hyperplasias, myopathy, enteropathy or spondylitic heart disease; in suppression of parathyroid hormone; in treatment of dermatological diseases, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism, asthma, cognitive impairment or senile dementia; in fertility control; in management of disorders involving blood clotting; or in reduction of serum cholesterol, which method comprises administering to said subject a therapeutically effective amount of an

active compound of formula (I) as claimed in any of claims 1 to 16.

21. A process for the preparation of a compound of
5 formula (I) as defined in claim 1 which comprises
reacting a compound containing a precursor for the
desired 17-position side chain in one or more stages and
with one or more reactants serving to form the said
desired 17-position side chain, followed if necessary
10 and/or desired by removal of any O-protecting group.

DECLARATION FOR PATENT APPLICATION AND APPOINTMENT OF ATTORNEY

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"Steroid compounds with a C17-alkyl side chain and an aromatic A-ring for use in therapy"

the specification of which (check one):

() is attached hereto, or (x) was filed on: **11 May 2000** as U.S. Application Serial No. or PCT International Application No.: **PCT/GB00/01813** and (if applicable) was amended on:

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in *Title 37, Code of Federal Regulations, § 1.56*. I hereby claim foreign priority benefits under *Title 35, United States Code, § 119* of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATION(S)			PRIORITY CLAIMED	
Number	Country	Day/Month/Year Filed	Yes	No
9910934.0	United Kingdom	11 May 1999	X	

I hereby claim the benefit under *Title 35, United States Code, § 119(e)* of any U.S. provisional applications listed below:

Application Number	Day/Month/Year filed

I hereby claim the benefit under *Title 35, United States Code, § 120* of any United States application(s) or PCT international application(s) designating The United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of *Title 35, United States Code, § 112*, I acknowledge the duty to disclose information which is material to patentability as defined in *Title 37, Code of Federal Regulations, § 1.56* which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Application Number	Filing date	Status - Patented, Pending or Abandoned
PCT/GB00/01813	11 May 2000	Pending


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of *Title 18 of the United States Code* and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: I(We) hereby appoint as my(our) attorneys, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office in connection therewith: J. Ernest Kenney, Reg. No. 19,179; Eugene Mar, Reg. No. 25,893; Richard E. Fichter, Reg. No. 26,382; Charles R. Wolfe, Jr., Reg. No. 28,680; Thomas J. Moore, Reg. No. 28,974; Bruce H. Troxell, Reg. No. 26,592; Joseph DeBenedictis, Reg. No. 28,502; and

I(we) authorize my(our) attorneys to accept and follow instructions from **Frank B. Dehn & Co.** regarding any matter related to the preparation, examination, grant and maintenance of this application, any continuation, continuation-in-part or divisional based thereon, and any patent resulting therefrom, until I(we) or my(our) assigns withdraw this authorization in writing.

Send correspondence to: **BACON & THOMAS**
625 Slaters Lane - 4th Floor
Alexandria, VA 22314

Telephone calls to: **Richard E. Fichter**
(703) 683-0500

Full Name of First or Sole Inventor Robert Henry HESSE	Citizenship American
Residence Address 6 Sargent Road, Winchester, MA 01890, USA MA	Post Office Address (x) Same as Residence
DATE 12/12/2007	SIGNATURE 

(x) See following page(s) for additional joint inventors.


DECLARATION FOR PATENT APPLICATION AND APPOINTMENT OF ATTORNEY

Page 2

200 Full Name of Joint Inventor Sundara Katugam Srinivasasetty SETTY	Citizenship American
Residence Address 402 Ringe Avenue, Cambridge, MA 02140, USA MA	Post Office Address (x)Same as Residence
DATE 12/12/2007	SIGNATURE X Sundara Setty
300 Full Name of Joint Inventor Malathi RAMGOPAL	Citizenship American
Residence Address 8 Garfield Lane East, Andover, MA 01810, USA MA	Post Office Address (x)Same as Residence
DATE 12/13/2001	SIGNATURE X Malathi Ramgopal
400 Full Name of Joint Inventor Sanga KUGABALASOORIAR	Citizenship Sri Lankan American
Residence Address 26 Boulder Drive, Burlington, MA 01803, USA MA	Post Office Address (x)Same as Residence
DATE 12/12/2007	SIGNATURE X Sanga Kugabala Sooriar

20062507 10:49:49

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



SCANNED, # _____

Application deficiencies found during scanning:

☐ Page(s) Page 64 of Specs were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ *Scanned copy is best available.*